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ABSTRACT: Glycosylations of 4,6-tethered glucosazide
donors with a panel of model acceptors revealed the effect
of acceptor nucleophilicity on the stereoselectivity of these
donors. The differences in reactivity among the donors were
evaluated in competitive glycosylation reactions, and their
relative reactivities were found to be reflected in the
stereoselectivity in glycosylations with a set of fluorinated
alcohols as well as carbohydrate acceptors. We found that the
2-azido-2-deoxy moiety is more β-directing than its C-2-O-
benzyl counterpart, as a consequence of increased destabiliza-
tion of anomeric charge development by the electron-
withdrawing azide. Additional disarming groups further
decreased the α-selectivity of the studied donors, whereas
substitution of the 4,6-benzylidene acetal with a 4,6-di-tert-
butyl silylidene led to a slight increase in α-selectivity. The C-2-dinitropyridone group was also explored as an alternative for the
nonparticipating azide group, but this protecting group significantly increased β-selectivity. All studied donors exhibited the same
acceptor-dependent selectivity trend, and good α-selectivity could be obtained with the weakest acceptors and most reactive
donors.
■ INTRODUCTION
Glucosamine is a key constituent in numerous important
oligosaccharides and glycoconjugates, where it can be either α-
or β-linked.1−5 Whereas the former type of linkage can be
reliably installed through the use of neighboring-group
participation of a C-2-amide- or carbamate-based protecting
group, the latter type continues to present a synthetic
challenge.6−8 A thorough understanding of the glycosylation
mechanism and the influence of both reaction partners and
reaction conditions on glycosylation stereoselectivity is needed
to enable reliable and predictable glycosylation reactions. The
in-depth research conducted on conformationally restricted
benzylidene mannose and glucose donors has provided
important insight into the glycosylation mechanisms of this
type of 1,2-cis-selective donor.9−17 To construct 1,2-cis linkages
of glucosamine donors, the C-2-amino group is most
commonly masked as the nonparticpating azide.18,19 Notably,
benzylidene glucosazides have not been systematically inves-
tigated with respect to the stereoselectivity of glycosylations in
which they are employed. The extrapolation of the stereo-
selectivity of benzylidene glucose donors to their glucosazide
counterparts suggests that benzylidene or analogously
protected glucosazides might represent an attractive class of
1,2-cis-selective glucosamine donor synthons.20,21
Recently, we advocated the use of a comprehensive set of
partially fluorinated ethanols, of gradually decreasing nucleo-
philicity, that can be used to map how the stereoselectivity of a
given glycosylation system is dependent on the nucleophilicity
of the acceptor.22 The stereoselectivity of the benzylidene
glucose donor system has proved to be greatly affected by the
reactivity of the nucleophile.23−27 In light of the demand for
1,2-cis-selective glucosaminylations but also with the aim in
mind of furthering the understanding of the stereoelectronic
effects exerted by the azido group, we set out to systematically
evaluate a series of glucosazide donors in a set of glycosylation
reactions involving the toolset of partially fluorinated ethanols
and a selection of carbohydrate acceptors. As we describe
herein, changes in the structure and reactivity of the donor can
be effectively mapped using our panel of model acceptors, and
we observed a clear reactivity−selectivity relationship for the
stereoselectivity of the glycosylations of all donors studied.
Differences among the donors and the stereochemical variation
in the glycosylation outcome can be explained on the basis of
competition experiments and the characterization of the
reactive intermediates involved.
■ RESULTS AND DISCUSSION
The set of (partially) fluorinated ethanol acceptors that we
recently employed to relate the glycosylation stereoselectivity
to the acceptor nucleophilicity is depicted in Figure 1
(compounds 6−11). Glycosylating these acceptors with
benzylidene mannose, benzylidene glucose, and mannuronic
acid donors, as well as fucosazide donors bearing various
protecting groups, established the dependence of the stereo-
selectivity of the glycosylations with these donors on the
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nucleophilicity of the acceptor.22,28 For benzylidene-protected
glucose donor 1, the gradual decrease in acceptor nucleophil-
icity going from ethanol to monofluoroethanol (MFE),
difluoroethanol (DFE), trifluoroethanol (TFE), and hexafluor-
oisopropanol (HFIP) led to a gradual shift of the stereo-
selecivity from high β-selectivity to exclusive α-selectivity (see
Table 3 below). Here, we present our results from investigating
the set of conformationally restricted glucosamine donors
depicted in Figure 1 (1−5). Variation in the structure of these
donors is found in the cyclic protecting groups (benzylidene vs
silylidene), in the functionality at the C-3-OH (benzyl vs
benzoyl), and in the nature of the C-2-N-protecting group
[azide vs the dinitropyridone (DNPY) group]. The DNPY
group is introduced here as a nonparticipating N-protecting
group.29,30 The reactivity and selectivity of the set of
glucosamine donors are related to the corresponding properties
of the well-studied benzylidene glucose donor 1.9,22
Synthesis. We prepared benzylidene-protected glucosazide
donors 331 and 432 with an O-benzyl and an O-benzoyl,
respectively, at C-3, as well as silylidene-protected donor 2,
from common building block 1233 as depicted in Scheme 1.
Hydrolysis of all acetyl esters and the trichloroacetamide was
followed by a diazotransfer to install the desired C-2-azide.34
Subsequent introduction of the di-tert-butylsilylidene (DTBS)
and the benzylidene acetal gave intermediates 1331 and 14,
respectively. Benzylation of 14 and 13 and benzoylation of 13
gave the target donor compounds 2, 3, and 4, respectively.
Donor 5 was prepared in two steps from thioglucoside 1535 by
exchange of the phthaloyl group for the DNPY functionality.
To this end, compound 15 was treated with ethylenediamine to
give amine 16, which was treated with DNPY reagent 1830,36 to
furnish the target donor.
Observation of Anomeric Triflates. With these five
donors in hand, we investigated the formation of potential
covalent reactive intermediates in low-temperature NMR
studies.37 The donors were treated with the diphenyl
sulfoxide/triflic anhydride (Ph2SO/Tf2O)
38 combination of
reagents in deuterated dichloromethane. Figure 2 shows the
results of these studies, and Table 1 summarizes the anomeric
chemical shifts of the observed triflates and the temperatures at
which decomposition starts (Tdecomp) [see also Supporting
Information (SI)]. Activation of reference donor 1 led to the
formation of two species: In addition to the anomeric triflate
19,9 the oxosulfonium triflate 19α* (6.68 ppm, 3.6 Hz) was
also formed, as was confirmed by the activation of a sample
containing additional Ph2SO (see SI). Donors 2 and 3 were
cleanly converted to their anomeric α-triflates 20 and 21,
respectively, by treatment with the activation couple at −80 °C.
Activation of donor 4 proceeded more slowly, and an increase
of the temperature from −80 to −35 °C was required for
complete activation. Donor 5 proved difficult to study by low-
temperature NMR spectroscopy because of significant line
broadening in the resonance sets for both the donor and the
products formed upon activation. Complete activation of the
thioglycoside could only be achieved at −40 °C, but at this
temperature, decomposition of the reactive intermediates also
set in. Two anomeric signals can be discriminated in the
spectrum of the activated DNPY donor 5 (Figure 2), and we
assign these as the intermediate triflate (6.06 ppm) and
oxosulfonium triflate (6.54 ppm). Unfortunately, complete
characterization was hampered by the severe line broadening.39
The reactive intermediates formed all decomposed to give the
glucal product 24. The formation of the glucal double bond is
relatively fast, as the proton at C-2 is readily eliminated to
provide the enol ether double bond that is conjugated to the
DNPY aromatic ring.
Competitive Glycosylations and Relative Reactivities.
To investigate the reactivities of donors 1−5, a series of
competitive glycosylations were performed between the
different thioglycosides.40−44 In these competition experiments,
we used an in situ activation protocol, employing N-
iodosuccinimide (NIS)/trifluoromethanesulfonic acid (TfOH)
as the activator and 2,3,4-tri-O-benzyl-α-O-methyl glucose (25)
as the acceptor, as is commonly done to determine the
reactivities of thioglycoside donors.45,46 It should be noted,
however, that the reactivity of the thiophenyl donor does not
directly compare with the reactivity of an intermediate triflate in
Figure 1. Glucose-configured donors 1−5 and model acceptors 6−11
used in this study.
Scheme 1. Preparation of Donors 2−5a
aReagents and conditions: (a) (i) K2CO3, EtOH, H2O; (ii) CuSO4·
5H2O, imidazole-1-sulfonyl azide hydrochloride;
34 (b) di-tert-butylsilyl
bis(trifluoromethanesulfonate), pyridine, 14 [71% (three steps)]; (c)
PhCH(OMe)2, p-TsOH·H2O, 13 [78% (three steps)]; (d) BnBr,
NaH, DMF, 2 (80%), 3 (89%); (e) BzCl, DMAP, pyridine, DCM
(90%); (f) ethylenediamine, EtOH (88%); (g) 18, AcOH/pyridine
(1:16, v/v) (98%); (h) K2CO3, NMP (85%); (i) HNO3, H2SO4
(60%).
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the glycosylation, although it does provide an indication of the
relative disarming or arming nature of the protecting groups
present on the different donors. It is apparent from Table 2 that
the azide has a profound effect on the reactivity of donor 3, as it
is completely outcompeted by the C-2-O-benzyl donor 1.46
Silylidene donor 2 is more reactive than donor 3, and the
disaccharide products derived from donors 2 and 3 are formed
in a 6:1 ratio. C-3-O-Benzyl donor 3 in turn outcompetes
benzoylated donor 4 slightly, as a result of the electron-
withdrawing nature of the benzoate, giving a 1.6:1 ratio of the
addition products 3C and 4C.47−49 DNPY-protected donor 5 is
the least reactive of the set of donors, as it did not provide any
disaccharide product in the competition experiment with donor
4.
Glycosylations. With the reactivities of these five donors
established, the series of glycosylations with model acceptors
6−11 and carbohydrate acceptors 25−2950−52 was undertaken
using the Ph2SO/Tf2O preactivation procedure. Table 3 list all
glycosylations ordered by acceptor and donor reactivities. A
clear relationship between the acceptor nucleophilicity and the
stereochemical outcome of the glycosylation reactions of all
studied glucosamine donors was observed, in line with the
results previously obtained with donor 1. Upon comparison of
the outcomes of the coupling reactions of glucosazide 3 with
Figure 2. 1H NMR spectra of activated donors 1−5 showing their respective anomeric triflates 19−23.
Table 1. Anomeric Triflates Observed
aValues determined at −40 °C.
Table 2. Competitive Donor Activations
entry donor I donor II productsa yieldb (%)
1 1 2 1C/2C, 14:1 65
2 1 3 1C/3C, 1:0 80
3 2 3 2C/3C, 6:1 37
4 3 4 3C/4C, 1.6:1 39
5c 4 5 4C/5C, 1:0 64
aDetermined by 1H NMR spectroscopy of the isolated disaccharide.
bThe disaccharide fraction was quantified after isolation by size-
exclusion chromatography and related to the limiting amount of NIS
(see Experimental Section). cThe combined donor concentration was
0.1 M, triflic acid was added at −20 °C, the reaction mixture was
heated to +15 °C overnight, and then the reaction was quenched
(Et3N).
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the results obtained using C-2-O-benzyl donor 1, it becomes
apparent that the latter donor reacts with higher α-selectivity.
Donor 2, bearing the DTBS group, overall provides slightly
more of the α-linked products than its benzylidene counterpart
3. The stereoselectivity of the condensations of donor 4,
bearing an additional electron-withdrawing protecting group
(i.e., the C-3-O-benzoyl), is very similar to the stereoselectivity
observed with C-3-O-benzyl donor 3. Finally, donor 5, carrying
the strongly electron-withdrawing DNPY group, is the most β-
selective of the series of donors listed in Table 3.53
The selectivities of glycosylations with carbohydrate accept-
ors were also found to vary in a nucleophilicity-dependent
fashion. The primary perbenzylated acceptor 25 reacted
similarly to ethanol 7 to give primarily the β-linked products
for all glucosamine donors studied. Secondary carbohydrate
acceptors that were less nucleophilic showed variations in
selectivity with the proportion of α-product increasing with
decreasing acceptor reactivity. In line with our previous studies,
the nucleophilicities of the secondary equatorial carbohydrate
alcohols fall somewhere between the reactivities of MFE and
DFE, with the reactivities of the axial hydroxyls approaching the
reactivity of TFE. The differences in the reactivities of the
donors are reflected in the stereoselectivities of both the
glycosylations that involve the model acceptors and the
glycosylations with the carbohydrate acceptors. A recurring
trend is apparent for all acceptors, with the most reactive donor
1 providing the most α-linked productand the least reactive
donor 5 giving the least α-linked product.
Mechanistic Discussion. Two major trends become
apparent from the table of glycosylations (Table 3). First,
Table 3. Glycosylations of Donors 1−5 with Model Acceptors 6−11 and Carbohydrate Acceptors 25−29
aGlycosylation results for donor 1 reported previously by van der Vorm et al.22 bRatio and yield of isolated product after column chromatography;
anomers were not separated. cOnly the hydrolyzed donor was found.
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with decreasing acceptor nucleophilicity, the α/β ratio
increases. Second, decreasing donor reactivity corresponds to
a decrease in the α/β ratio. These trends also emerged during
our previous studies involving benzylidene glucose, mannose,
mannuronic acid, and fucosazide donors.22,28 The reactive
intermediates that can play a role in the glycosylations of the
conformationally restricted glucosamine donors and the
reaction trajectories of the incoming nucleophiles are presented
in Figure 3. Previous studies by the group of Crich have
indicated that substitutions on the benzylidene glucosyl triflate
19 proceed in an SN2-like manner. In those mechanistic studies,
which involved the determination of kinetic isotope effects and
cation-clock methodology, isopropanol was used as an
acceptor.12,14 In the kinetic scenario that was proposed, the
relatively stable α-trilfate (observed by low-temperature NMR
spectroscopy) is in equilibrium with its more reactive β-
counterpart. In both species, the triflate can be displaced by
alcohols if they are nucleophilic enough. The higher β-
selectivity that is seen for the glucosazide and DNPY-
glucosamine donors in comparison to donor 1 can be explained
by the stronger electron-withdrawing effect of the azide with
respect to the benzyl ether. This leads to a more stable covalent
α-triflate and favors an associative displacement mechanism. A
similar effect was observed by the group of Crich in
glycosylations of the analogous 2-deoxy-2-fluoro benzylidene
glucosides.54 The DNPY group is even more electron-
withdrawing, leading to a further increase in β-selectivity
through associative displacement. However, an SN2-like
reaction pathway is less likely for the weaker nucleophiles,
such as TFE and HFIP. The high α-selectivity for these
acceptors can be explained perhaps more precisely by
considering the involvement of more electrophilic intermedi-
ates such as the glycosyl oxocarbenium ion. The benzylidene
and silylidene protecting groups restrict the conformational
space that the donor pyranosides can adopt, and the
intermediate oxocarbenium ion likely adopt a 3E/3H4-like
conformation.55,56 Nucleophiles attack this envelope/half-chair
conformer preferentially from the bottom face to lead to the α-
linked prodcuts through a chairlike transition state.57 The more
reactive donors more readily dissociate to form an oxocarbe-
nium ion, and this accounts for the increased α-selectivity for
these donors. Donor 2, bearing the silylidene group is the most
reactive of the studied glucosamine donors. It also is slightly
more flexible than the benzylidene restricted donors, and these
two factors allow the activated donor to more readily form a
flattened oxocarbenium ion-like intermediate. Consequently, it
is the most α-selective of the studied glucosamine donors.
Finally, it is notable that the C-3-O-benzoyl-protected
glucosazide 4 reacts in a slightly more β-selective fashion
than its C-3-O-benzyl counterpart 3. In light of the discussion
above, this makes sense, as the electron-withdrawing benzoyl
stabilizes the anomeric α-triflate. It contrasts, however, with the
behavior of acyl groups at the C-3 position of benzylidene
mannosyl donors. The 1,2-cis selectivity generally observed for
these donors can be completely changed to selectively give the
α-linked products by installing a C-3-O-acyl group in the
donor.58,59 The difference between the benzylidene mannose
and benzylidene glucose series can be found in the different
geometries that the oxocarbenium ions adopts. For the
benzylidene mannose system, a B2,5-like structure is one of
the lower-energy oxocarbenium ion conformers.12,55,56 In this
constellation, the C-3-benzoate can fold over to the electron-
depleted anomeric center to provide stabilization, without a
major skeletal rearrangement. For the benzylidene glucose, on
the other hand, a B2,5-like structure such as 32 is significantly
less favorable because this puts the C-2-azide in a flagpole
position. Given the selectivities observed for this donor,
influences arising from this boat conformation do not play a
significant role here.
■ CONCLUSIONS
A set of model acceptors of gradually changing nucleophilicity
has been used to investigate how the stereochemistry of
glycosylations involving 4,6-tethered glucosamine donors
relates to the nucleophilicity of the acceptor. The set of
acceptors was complemented by a suite of carbohydrate
alcohols to translate the results obtained with the model
acceptors to a more relevant glycosylation setting. Four
glucosamine donors were probed that differed in the type of
tether spanning the C-4 and C-6 alcohols, the nature of the
protecting group at the C-3-OH, and the nature of the amino
functionality at C-2. Similarly to the previously described
benzylidene glucose donor 1, the stereoselectivity of the studied
glucosamine donors show a strong correlation to the
nucleophilicity of the acceptor, with strong nucleophiles
providing completely β-selective condensations and weak
nucleophiles selectively leading to the formation of the α-
linked products. Benzylidene glucosazide donors are less α-
Figure 3. Reactive intermediates and reaction pathways for the 4,6-tethered glucosazide donors.
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selective than their C-2-O-benzyl congeners, because of the
increased electron-withdrawing power of the azide, which
retards the formation of an oxocarbenium ion species and
favors a more associative mechanistic pathway. We have also
introduced a novel protecting group for the C-2-amino group:
the dinitropyridone functionality.29,30,36 Although this group is
easily installed and removed from the C-2-amine, its strongly
electron-withdrawing character limits its use. In the 4,6-
benzylidene glucosamine donor studied here, it disarms the
donor glycoside to the extent that it turns into a suboptimal
glycosyl donor. A major incentive for the reported study was
the good to excellent α-selectivity that has previously been
reported for benzylidene glucose donor 1. Unfortunately,
installation of a 4,6-benzylidene on the analogous glucosazide
donors does not provide a reliable donor to affect 1,2-cis-
selective glycosylations. Only with relatively poor nucleophiles
are useful stereoselectivities obtained. Changing the benzyli-
dene for a silylidene group, however, turns the donor into a
more reactive glycosylating agent showing improved α-
selectivity. This donor, attractive because of its fully orthogonal
protecting group scheme, might find application in the future
assembly of oligosaccharides featuring α-glucosamines. Finally,
we note that this study provides another illustration of the
application of the toolset of partially fluorinated ethanols to
efficiently map the reactivity−selectivity relationship of a class
of donor glycosides. Implementation of this methodology to
investigate novel donor systems will provide broader insights
into the different mechanistic pathways at play during
glycosylations and eventually generate a complete picture of
how to tune both reaction partners to achieve stereoselective
glycosylation reactions in a predictable manner.
■ EXPERIMENTAL SECTION
General Experimental Procedures. All chemicals were of
commercial grade and were used as received unless stated otherwise.
Dichloromethane (DCM) was stored over activated 4 Å molecular
sieves for at least 24 h before use. Trifluoromethanesulfonic anhydride
(Tf2O) was distilled over P2O5 and stored at −20 °C under a nitrogen
atmosphere. Triethylamine (Et3N) was distilled over CaH2 and stored
over KOH pellets. Overnight temperature control was achieved with
an FT902 immersion cooler (Julabo). Flash column chromatography
was performed on silica gel 60 Å (0.04−0.063 mm, Screening Devices
B.V.). Size-exclusion chromatography was performed on Sephadex
(LH-20, GE Healthcare Life Sciences) by isocratic elution with DCM/
MeOH (1:1, v/v). Thin-layer chromatography (TLC) analysis was
conducted on TLC silica gel 60 (Kieselgel 60 F254, Merck) with UV
detection (254 nm) and by spraying with 20% sulfuric acid in ethanol
or by spraying with a solution of (NH4)6Mo7O24·H2O (25 g/L) and
(NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% aqueous sulfuric acid
followed by charring at ±250 °C. High-resolution mass spectroscopy
(HRMS) was performed on a Thermo Finnigan LTQ Orbitrap mass
spectrometer equipped with an electrospray ion source in positive-ion
mode (source voltage 3.5 kV, sheath-gas flow rate 10, capillary
temperature 275 °C) with a resolution of R = 60.000 at m/z 400 (mass
range of 150−4000). 1H and 13C NMR spectra were recorded on
Bruker AV-400, Bruker DMX-400, and Bruker AV-500 NMR
instruments. Chemical shifts (δ) are given in parts per million
(ppm) relative to tetramethylsilane as an internal standard or the
residual signal of the deuterated solvent. Coupling constants (J) are
given in hertz (Hz) . All presented 13C-attached proton test (APT)
spectra are proton-decoupled. NMR peak assignments were made
using correlation spectroscopy (COSY) and heteronuclear single-
quantum coherence (HSQC). If necessary, additional nuclear
Overhauser enhancement spectroscopy (NOESY), heteronuclear
multiple-bond correlation (HMBC), and gated HMBC (HMBC-
GATED) experiments were used to further elucidate the structure.
The anomeric product ratios were based on careful analysis of the
crude reaction mixture and the purified reaction product by integration
of representative 1H NMR signals. IR spectra were recorded on a
Shimadzu FTIR-8300 IR spectrometer and are reported in wave-
numbers (cm−1). Specific rotations were measured on a Propol
automatic polarimeter or an Anton-Paar MCP-100 modular circular
polarimeter at 589 nm unless otherwise stated.
General Procedure for Tf2O/Ph2SO-Mediated Glycosyla-
tions. Donor (0.1 mmol), Ph2SO (26 mg, 0.13 mmol, 1.3 equiv),
and TTBP60 (62 mg, 0.25 mmol, 2.5 equiv) were coevaporated twice
with dry toluene and dissolved in dry DCM (2 mL, 0.05 M donor).
Activated 3 Å molecular sieves (rods, 1/16 in. in size) were added, and
the reaction mixture was stirred for 1 h at room temperature under a
nitrogen atmosphere. The solution was cooled to −78 °C, and Tf2O
(22 μL, 0.13 mmol, 1.3 equiv) was added. The reaction mixture was
allowed to warm to −60 °C (donors 1, 2, and 3), −45 °C (donor 5),
and −35 °C (donor 4) and then recooled to −78 °C, after which the
acceptor (0.2 mmol, 2 equiv) in DCM (0.4 mL, 0.5 M) was added.
The reaction mixture was allowed to warm to −40 °C in
approximately 90 min and stirred for an additional 0−18 h depending
on the acceptor. The reaction was quenched with Et3N (0.1 mL, 0.72
mmol, 5.5 equiv) at −40 °C, and the mixture was diluted with DCM.
The solution was transferred to a separatory funnel, water was added,
the layers were separated, and the water phase was extracted once
more with DCM. The combined organic layers were dried over
MgSO4, filtered, and concentrated in vacuo. Purification by silica gel
flash column chromatography and, when needed, sephadex LH-20
size-exclusion chromatography yielded the glycosylation product as a
mixture of anomers.
General Procedure for NIS/TfOH-Mediated Competition
Experiments. Donor I (0.1 mmol, 1 equiv), donor II (0.1 mmol, 1
equiv), and acceptor 25 (0.2 mmol, 2 equiv) were together
coevaporated with dry toluene (2×). Dry DCM (4 mL, donor
concentration of 0.05 M), a Teflon stirring bar, and 3 Å activated
molecular sieves (rods, 1/16 in. in size) were added, and the mixture
was stirred under a nitrogen atmosphere for 1 h at room temperature.
The mixture was cooled to −40 °C, NIS (0.1 mmol, 1 equiv) was
added. TfOH (50 μL of a freshly prepared 0.2 M stock solution in dry
DCM, 0.1 equiv) was added, and the mixture was allowed to warm to
0 °C in 3 h. Et3N (0.1 mL) was added, and the mixture was diluted
with EtOAc, washed with saturated aqueous NaS2O3 and brine, dried
over Na2SO4, and concentrated in vacuo. Size-exclusion chromatog-
raphy (Sephadex LH-20, 1:1 DCM/MeOH) enabled isolation of the
disaccharide products and the monosaccharide remainders, which were
both analyzed by NMR spectroscopy. The yield of the disaccharide
fraction was determined. For the competition between donors 4 and 5,
a 0.1 M concentration and a starting temperature of −20 °C were
used, and the mixture was allowed to warm to +15 °C in 18 h.
General Procedure for Low-Temperature NMR Experiments.
A mixture of donor (30 μmol) and Ph2SO (39 μmol) was
coevaporated with dry toluene twice. [For the activation of donor 1,
TTBP (75 μmol) was also added.] Under a nitrogen atmosphere,
CD2Cl2 (0.6 mL) was added, and the mixture was transferred to a
nitrogen-flushed NMR tube that was then closed with an NMR tube
septum. The NMR magnet was cooled to −80 °C, locked, and
shimmed and the sample was measured prior to activation. In a long
narrow cold bath (EtOH, −85 °C) the sample was treated with Tf2O
(39 μmol), shaken thrice, and cooled again after each shaking. The
cold sample was wiped dry and quickly inserted back in the cold
magnet. The first 1H NMR spectrum was immediately recorded. The
sample was then reshimmed, and spectra were recorded in 10 °C
intervals with at least 5 min of equilibration time for every
temperature.
Phenyl 2-Azido-4,6-O-benzylidene-2-deoxy-1-thio-β-D-glucopyr-
anoside (13). To a suspension of thioglycoside 1233 (27.14 g, 50
mmol, 1 equiv) in EtOH (200 mL) were added K2CO3 (41.5 g, 300
mmol, 6 equiv) and 20 mL of H2O, and the mixture was refluxed
overnight. The flask was cooled to room temperature, and to the crude
free amine61 was added the diazo transfer reagent imidazole-1-sulfonyl
azide hydrochloride34 (13.10 g, 62.5 mmol, 1.25 equiv) in three equal
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portions, followed by a catalytic amount of CuSO4·5 H2O (125 mg,
0.5 mmol, 0.01 equiv). After the solution had been stirred for 5 h, it
was filtered and reduced to one-fourth its volume in vacuo. H2O (150
mL) and 1 M aqueous HCl (150 mL) were added to obtain an acidic
(pH ∼3) solution, which was extracted with EtOAc (3 × 120 mL).
The combined organic layers were washed with saturated aqueous
NaHCO3 (150 mL) and brine (150 mL), dried with MgSO4, and
concentrated in vacuo to obtain the crude azide phenyl 2-azido-2-
deoxy-1-thio-β-D-glucopyranoside.62 The crude azide (≤50 mmol) was
coevaporated with toluene twice and subsequently dissolved in DMF
(50 mL) and MeCN (200 mL) to which benzaldehyde dimethyl acetal
(15 mL, 100 mmol, 2 equiv) and p-TsOH·H2O (950 mg, 5 mmol, 0.1
equiv) had been added. The reaction mixture was heated at 60 °C
overnight and then heated at 60 °C for an additional 5 h under
reduced pressure (300 mbar) to reduce the volume to one-third. The
reaction was quenched by the addition of triethylamine (1 mL), and
the reaction mixture was diluted with EtOAc (350 mL) and washed
with H2O (2 × 100 mL), saturated aqueous NaHCO3 (1 × 100 mL),
and brine (1 × 100 mL). The organic layer was dried (MgSO4) and
concentrated in vacuo. The crude mixture was purified by percipitation
from hot EtOAc (100 mL)/heptane (300 mL) through the addition of
petroleum ether (500 mL) as the mixture was stirred and slowly
cooled to 0 °C to obtain the title compound as a white powder (11.38
g, 29.5 mmol, 59%). The mother liquors were purified by flash column
chromatography (8:1 to 4:1 pentane/EtOAc) to obtain an additional
batch of white solid product (3.8 g, 9.6 mmol, total yield = 39.1 mmol,
78%, three steps). A purified sample could be recrystallized from either
hot MeOH or EtOAc/petroleum ether to obtain white cotton-like
needles. Rf 0.50 (6:1 pentane/EtOAc). Spectroscopic data were in
accord with those reported previously.31 1H NMR (CDCl3, 400 MHz,
H−H COSY, HSQC): δ 7.64−7.52 (m, 2H, CHarom), 7.50−7.43 (m,
2H, CHarom), 7.42−7.32 (m, 6H, CHarom), 5.53 (s, 1H, CHPh), 4.54
(d, 1H, J = 10.1 Hz, H-1), 4.38 (dd, 1H, J = 10.5, 4.6 Hz, H-6), 3.85−
3.70 (m, 2H, H-3, H-6), 3.52−3.40 (m, 2H, H-4, H-5), 3.35 (dd, 1H, J
= 10.2, 9.0 Hz, H-6), 2.75 (bs, 1H, 3-OH). 13C-APT NMR (CDCl3,
101 MHz, HSQC): δ 136.8 (Cq CHPh), 133.8 (CHarom), 130.9 (Cq
SPh), 129.6, 129.3, 128.8, 128.5, 126.4 (CHarom), 102.1 (CHPh), 86.9
(C-1), 80.3 (C-4), 74.2 (C-3), 70.4 (C-5), 68.5 (C-6), 65.2 (C-2).
HRMS: [M + H]+ calcd for C19H20N3O4S 386.11690, found
386.11708.
Phenyl 2-Azido-2-deoxy-4,6-O-di-tert-butylsilylidene-1-thio-β-D-
glucopyranoside (14). Crude triol phenyl 2-azido-2-deoxy-1-thio-β-
D-glucopyranoside (synthesized as described for compound 13) (≤10
mmol) was dissolved in pyridine (15 mL) and cooled to 0 °C. Di-tert-
butylsilyl bis(trifluoromethanesulfonate) (3.6 mL, 11 mmol, 1.1 equiv)
was slowly added, and the mixture was stirred for 1 h before the
reaction was quenched with MeOH. The reaction mixture was diluted
with 200 mL of Et2O and washed with 1 M aqueous HCl (3 × 60 mL),
saturated aqueous NaHCO3 (60 mL), and brine (60 mL). The organic
layer was dried with Na2SO4, filtered, and concentrated in vacuo.
Purification by flash column chromatography (1−10% Et2O/pentane)
afforded the silylidene-protected title compound as a colorless oil
(3.10 g, 7.1 mmol, 71% over three steps). Rf 0.18 (19:1 pentane/
Et2O). [α]D
23 = −42.6° (c = 1.0, CHCl3). IR (neat): 652, 733, 824,
1072, 1092, 1155, 1277, 1474, 2112, 2859, 2884, 2934, 2963, 3449. 1H
NMR (CDCl3, 400 MHz, H−H COSY, HSQC) δ 7.57−7.51 (m, 2H,
CHarom), 7.36−7.31 (m, 3H, CHarom), 4.49 (d, 1H, J = 10.2 Hz, H-1),
4.21 (dd, 1H, J = 10.2, 5.1 Hz, H-6), 3.89 (t, 1H, J = 10.2 Hz, H-6),
3.64 (t, 1H, J = 9.1 Hz, H-4), 3.56 (td, 1H, J = 9.0, 1.2 Hz, H-3), 3.40
(ddd, 1H, J = 10.1, 9.3, 5.1 Hz, H-5), 3.31 (dd, 1H, J = 10.2, 9.1 Hz, H-
2), 2.92 (d, 1H, J = 1.6 Hz, 3-OH), 1.04 (s, 9H, CH3
tBu), 0.97 (s, 9H,
CH3
tBu). 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 133.7
(CHarom), 131.2 (Cq), 129.2, 128.7 (CHarom), 86.8 (C-1), 77.4 (C-3),
76.6 (C-4), 74.4 (C-5), 66.0 (C-6), 64.4 (C-2), 27.5, 27.0 (CH3
tBu),
22.8, 20.0 (Cq
tBu). HRMS: [M − N2 + H]+ calcd for C20H32NO4SSi
410.18213, found 410.18220.
Phenyl 2-Azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-
1-thio-β-D-glucopyranoside (2). Compound 14 (1.4 g, 3.2 mmol) was
dissolved in DMF (15 mL) and cooled to 0 °C. Benzyl bromide (421
μL, 3.52 mmol, 1.1 equiv) and NaH (60% dispersion in mineral oil,
166 mg, 4.16 mmol, 1.3 equiv) were added, and the reaction mixture
was stirred for 2 h at 0 °C and then for 1 h at room temperature. The
reaction was quenched with MeOH, and H2O (100 mL) was added.
The water phase was extracted three times with 30 mL of Et2O, and
the combined organic layers were washed with brine (2×), dried with
Na2SO4, and concentrated under reduced pressure. Purification by
flash column chromatography (1%−8% Et2O/pentane) yielded
compound 2 as a colorless oil (1.35 g, 2.56 mmol, 80%). Additional
impurities as observed by 1H NMR spectroscopy originating from the
previous crude steps could be removed by size-exclusion chromatog-
raphy (Sephadex LH-20, 1:1 DCM/MeOH). Rf 0.51 (19:1 pentane/
Et2O). [α]D
23 = −85.0° (c = 1.0, CHCl3). IR (neat): 654, 694, 746, 766,
826, 1059, 1078, 1099, 1159, 1474, 2110, 2859, 2884, 2934, 2963. 1H
NMR (CDCl3, 400 MHz, H−H COSY, HSQC): δ 7.55−7.48 (m, 2H,
CHarom), 7.43−7.37 (m, 2H, CHarom), 7.36−7.27 (m, 6H, CHarom),
4.99 (d, 1H, J = 10.7 Hz, CHH Bn), 4.81 (d, 1H, J = 10.7 Hz, CHH
Bn), 4.41 (d, 1H, J = 10.2 Hz, H-1), 4.21 (dd, 1H, J = 10.3, 5.1 Hz, H-
6), 3.90 (t, 1H, J = 10.2 Hz, H-6), 3.87 (dd, 1H, J = 9.5, 8.7 Hz, H-4),
3.48−3.38 (m, 2H, H-3, H-5), 3.28 (dd, 1H, J = 10.2, 9.2 Hz, H-2),
1.07 (s, 9H, CH3
tBu), 1.01 (s, 9H, CH3
tBu). 13C-APT NMR (CDCl3,
101 MHz, HSQC): δ 137.9 (Cq Bn), 133.9 (CHarom), 130.9 (Cq SPh),
129.1, 128.7, 128.5, 128.5, 128.1 (CHarom), 86.4 (C-1), 84.2 (C-3),
77.8 (C-4), 75.7 (CH2 Bn), 74.7 (C-5), 66.2 (C-6), 64.2 (C-2), 27.5,
27.1 (CH3
tBu), 22.7, 20.0 (CH3
tBu). HRMS: [M + H]+ calcd for
C27H38N3O4SSi 528.23468, found 528.23451; [M − N2 + H]+ calcd
for C27H38NO4SSi 500.22853, found 500.22839.
Phenyl 2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-1-thio-β-
D-glucopyranoside (3). Compound 13 (4.36 g, 11.3 mmol) was
coevaporated once with dry toluene and then dissolved in DMF (50
mL) and cooled to 0 °C. Benzyl bromide (1.9 mL, 15.8 mmol, 1.4
equiv) and NaH (60% dispersion in mineral oil, 900 mg, 22.6 mmol, 2
equiv) were added in succession, and the reaction mixture was stirred
at room temperature for 4.5 h. MeOH (5 mL) was slowly added, and
the reaction mixture was diluted with EtOAc (150 mL) and washed
with H2O (2 × 60 mL) and brine (50 mL). The organic layer was
dried (MgSO4), filtered, and concentrated in vacuo. The crude
product was purified by crystallization (10 mL of hot EtOAc, addition
of 100 mL of petroleum ether) to yield the title compound as a white
cotton-like solid (4.79 g, 10.1 mmol, 89%). Rf 0.71 (8:1 pentane/
EtOAc). Spectroscopic data were in accord with those reported
previously.31 1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC): δ
7.56 (ddt, 2H, J = 5.0, 3.4, 1.5 Hz, CHarom), 7.47 (dd, 2H, J = 7.5, 2.3
Hz, CHarom), 7.42−7.26 (m, 11H, CHarom), 5.57 (s, 1H, CHPh), 4.91
(d, 1H, J = 10.9 Hz, CHH Bn), 4.78 (d, 1H, J = 10.9 Hz, CHH Bn),
4.49 (d, 1H, J = 10.2 Hz, H-1), 4.39 (dd, 1H, J = 10.6, 5.0 Hz, H-6),
3.79 (t, 1H, J = 10.3 Hz, H-6), 3.71−3.59 (m, 2H, H-3, H-4), 3.52−
3.42 (m, 1H, H-5), 3.41−3.32 (m, 1H, H-2). 13C-APT NMR (CDCl3,
101 MHz, HSQC): δ 137.6, 137.1 (Cq), 134.0 (CHarom), 130.6 (Cq
SPh), 129.2, 129.2, 128.8, 128.5, 128.4, 128.4, 128.1, 126.0 (CHarom),
101.3 (CHPh), 86.5 (C-1), 81.3, 81.0 (C-3, C-4), 75.3 (CH2 Bn), 70.5
(C-5), 68.5 (C-6), 64.6 (C-2). HRMS: [M + H]+ calcd for
C26H26N3O4S 476.16385, found 476.16375.
Phenyl 2-Azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-1-thio-
β-D-glucopyranoside (4). To a 0 °C solution of compound 13
(1.34 g, 3.48 mmol) in DCM (17 mL) and pyridine (1.4 mL, 34.8
mmol, 5 equiv) were added benzoyl chloride (0.61 mL, 5.22 mmol, 1.5
equiv) and DMAP (42 mg, 0.35 mmol, 0.1 equiv). The reaction
mixture was allowed to stir overnight, after which H2O and DCM were
added. The organic layer was separated and washed with saturated
aqueous NaHCO3 and brine. The organic layer was dried with MgSO4
and concentrated in vacuo. Flash column chromatography (19:1 to 8:1
pentane/EtOAc) afforded the title compound as a white solid (1.54 g,
3.15 mmol, 90%). The product could be recrystallized from EtOAc
and petroleum ether to yield a fluffy white solid. Rf 0.53 (8:1 pentane/
EtOAc). Spectroscopic data were in accord with those reported
previously.63 1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC): δ
8.05 (d, 2H, J = 7.3 Hz, CHarom), 7.59 (dd, 2H, J = 6.5, 3.1 Hz,
CHarom), 7.53 (t, 1H, J = 7.4 Hz, CHarom), 7.44−7.33 (m, 7H, CHarom),
7.29−7.23 (m, 3H, CHarom), 5.52 (t, 1H, J = 9.6 Hz, H-3), 5.46 (s, 1H,
CHPh), 4.69 (d, 1H, J = 10.1 Hz, H-1), 4.38 (dd, 1H, J = 10.5, 4.9 Hz,
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.7b00470
J. Org. Chem. 2017, 82, 4793−4811
4799
H-6), 3.79 (t, 1H, J = 10.2 Hz, H-6), 3.71 (t, 1H, J = 9.5 Hz, H-4),
3.62−3.53 (m, 2H, H-2, H-5). 13C-APT NMR (CDCl3, 101 MHz,
HSQC): δ 165.3 (CO Bz), 136.7 (Cq), 133.7, 133.4 (CHarom),
130.8 (Cq), 129.9, 129.3 (CHarom), 129.2 (Cq), 129.1, 128.8, 128.5,
128.2, 126.1 (CHarom), 101.3 (CHPh), 87.1 (C-1), 78.4 (C-4), 73.5
(C-3), 70.7 (C-5), 68.3 (C-6), 63.9 (C-2). HRMS: [M + H]+ calcd for
C26H24N3O5S 490.14312, found 490.14305.
Phenyl 2-Amino-3-O-benzyl-4,6-O-benzylidene-2-deoxy-1-thio-
β-D-glucopyranoside (16). Fully protected glycoside 1535 (9.11 g,
15.7 mmol) was dissolved in 160 mL of EtOH and heated to reflux,
after which ethylene diamine (52 mL, 785 mmol, 50 equiv) was added
in three portions and reflux was maintained overnight. The reaction
mixture was concentrated under reduced pressure and mixed with
toluene (100 mL) and 45 g of silica gel, and the mixture was
evaporated to dryness. Column chromatography (8:2 to 2:1 pentane/
EtOAc) gave the free amine as a white solid (6.19 g, 13.76 mmol,
88%) that could be recrystallized in EtOAc/petroleum ether. Rf 0.40
(2:1 pentane/EtOAc). mp 136.1−137.5 °C. [α]D20 = −33.5° (c = 0.57,
CHCl3). IR (thin film): 698, 748, 1026, 1069, 1123, 1371, 1452, 1583,
2870, 3030, 3059. 1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC):
δ 7.56−7.44 (m, 4H, CHarom), 7.42−7.24 (m, 11H, CHarom), 5.59 (s,
1H, CHPh), 4.99 (d, 1H, J = 11.3 Hz, CHH Bn), 4.68 (d, 1H, J = 11.2
Hz, CHH Bn), 4.58 (d, 1H, J = 9.9 Hz, H-1), 4.38 (dd, 1H, J = 10.5,
5.0 Hz, H-6), 3.81 (t, 1H, J = 10.3 Hz, H-6), 3.72 (t, 1H, J = 9.2 Hz,
H-4), 3.59 (t, 1H, J = 9.0 Hz, H-3), 3.52 (td, 1H, J = 9.7, 4.9 Hz, H-5),
2.91 (t, 1H, J = 9.4 Hz, H-2), 1.75 (bs, 2H, NH2).
13C-APT NMR
(CDCl3, 101 MHz, HSQC): δ 138.2, 137.4 (Cq), 133.0 (CHarom),
131.8 (Cq SPh), 129.1, 128.6, 128.4, 128.3, 128.3, 128.0, 126.0
(CHarom), 101.3 (CHPh), 89.6 (C-1), 82.2, 82.2 (C3, C-4), 75.1 (CH2
Bn), 70.7 (C-5), 68.8 (C-6), 55.5 (C-2). HRMS: [M + H]+ calcd for
C26H28NO4S 450.17336, found 450.17238.
1-(4-Nitrophenyl)-4-pyridone (17). Following the procedure of
You and Twieg,64 4-hydroxypyridine (14.3 g, 150 mmol), 4-
chloronitrobenzene (22.9 g, 145 mmol), and K2CO3 (20.7 g, 150
mmol) were suspended in N-methyl-2-pyrrolidone (110 mL) and
heated at 150 °C for 2 h. The hot solution was then poured directly
onto ice and allowed to precipitate until all of the ice had melted. The
suspension was then filtered and washed four times with cold H2O.
The resulting solid was dried under a vacuum at 100 °C until dry.
Yield: 26.6 g, 123 mmol, 85%. IR (neat): 606, 692, 741, 752, 843,
1015, 1111, 1198, 1285, 1339, 1495, 1514, 1582, 1638, 3071. 1H NMR
(DMSO, 400 MHz, H−H COSY, HSQC): δ 8.38 (d, 2H, J = 9.1 Hz),
8.14 (d, 2H, J = 7.8 Hz), 7.86 (d, 2H, J = 9.1 Hz), 6.29 (d, 2H, J = 7.8
Hz). 13C-APT NMR (DMSO, 101 MHz, HSQC): δ 177.6, 147.1,
145.9, 139.2, 125.3, 123.2, 118.3. HRMS: [M + H]+ calcd for
C11H9N2O3 217.06077, found 217.06074.
3,5-Dinitro-1-(4-nitrophenyl)-4-pyridone (18). In a modification of
the procedure of Matsumura et al.,30 an ice-cooled three-neck flask
equipped with a condenser was charged with 120 mL of H2SO4 (30%
SO3), and then 120 mL of fuming 99% HNO3 was slowly added. To
this cold mixture was added pyridone 17 (21.6 g, 100 mmol) in small
portions. When addition was complete, the mixture was slowly
brought to 130 °C and stirred for 40 h. The mixture was allowed to
cool and then poured over ice, stirred for 3 h, filtered, and washed
three times with cold water. Yield: 18.4 g, 60 mmol, 60%. Purity
(NMR): 90%. Tetranitro [3,5-dinitro-1-(2,4-dinitrophenyl)-4-pyri-
done 1H NMR (DMSO, 400 MHz): δ 9.42 (s, 2H), 9.05 (d, 1H, J
= 2.6 Hz), 8.87 (dd, 1H, J = 8.8, 2.6 Hz), 8.32 (d, 1H, J = 8.7 Hz)] and
dinitro [3-nitro-1-(4-nitrophenyl)-4-pyridone 1H NMR (DMSO, 400
MHz): δ 9.18 (d, 1H, J = 2.5 Hz), 8.43 (d, 2H, J = 9.0 Hz), 8.26 (dd,
1H, J = 7.8, 2.5 Hz), 7.99 (d, 2H, J = 9.1 Hz), 6.68 (d, 1H, J = 7.9 Hz)]
impurities were present (ratios varied slightly upon repetition). IR
(neat): 717, 768, 789, 853, 910, 1141, 1261, 1306, 1350, 1449, 1514,
1591, 1672, 3076. 1H NMR (DMSO, 400 MHz): δ 9.38 (s, 1H), 8.47
(d, 1H, J = 9.0 Hz), 8.05 (d, 1H, J = 9.1 Hz). 13C-APT NMR (DMSO,
101 MHz): δ 159.3, 147.6, 145.5, 142.1, 141.6, 125.7, 125.1. HRMS:
[M + H]+ calcd for C11H7N4O7 307.03093, found 307.03123.
Phenyl 2-(3,5-Dinitro-4-pyridone)-3-O-benzyl-4,6-O-benzylidene-
2-deoxy-1-thio-β-D-glucopyranoside (5). Free amine 16 (3.6 g, 8
mmol) and reagent 18 (2.7 g, 8.8 mmol, 1.1 equiv) were dissolved in
pyridine (48 mL) and AcOH (4 mL) and left to stir for 30 min. The
mixture was diluted with EtOAc and washed with 1 M aqueous HCl
(5×) and saturated aqueous NaHCO3 (1×). The organic layer was
dried (MgSO4), filtered, and concentrated under reduced pressure.
Column chromatography: DCM until all of the nitroanaline had been
removed, followed by 1% to 5% acetone in DCM. Yield: 4.84 g, 7.8
mmol (98%) as a yellow solid. Rf 0.21 (DCM), [α]D
20 = 10.5° (c = 0.5,
CHCl3). IR (thin film): 604, 696, 746, 989, 1055, 1094, 1211, 1300,
1329, 1516, 1674, 2856, 2926, 3034, 3059. 1H NMR (acetone-d6, 400
MHz, H−H COSY, HSQC): δ 8.74 (s, 2H, CH pyridone), 7.63−7.54
(m, 2H, CHarom), 7.51−7.39 (m, 5H, CHarom), 7.39−7.31 (m, 3H,
CHarom), 7.21−7.14 (m, 3H, CHarom), 7.14−7.07 (m, 2H, CHarom),
5.84 (s, 1H, CHPh), 5.73 (d, 1H, J = 10.4 Hz, H-1), 4.84 (d, 1H, J =
12.1 Hz, CHH Bn), 4.62 (d, 1H, J = 12.1 Hz, CHH Bn), 4.55−4.47
(m, 1H, H-3), 4.44−4.39 (m, 1H, H-6), 4.39 (t, 1H, J = 8.9 Hz, H-2),
4.06−3.91 (m, 3H, H-4, H-5, H-6). 13C-APT NMR (acetone-d6, 101
MHz, HSQC): δ 159.9 (CO pyridone), 143.1 (Cq NO2), 138.5,
137.8 (Cq), 133.4 (CHarom), 131.7 (Cq SPh), 130.3, 129.7, 129.5,
129.2, 129.0, 129.0, 127.0 (CHarom), 102.0 (CHPh), 85.9 (C-1), 83.0
(C-4), 77.0 (C-3), 74.7 (CH2 Bn), 71.6 (C-2), 70.9 (C-5), 68.8 (C-6).
HRMS: [M + H]+ calcd for C31H28N3O9S 618.15408, found
618.15375.
Trifluoromethanesulfonyl 2,3-Di-O-benzyl-4,6-O-benzylidene-α-
D-glucopyranoside (19).9 1H NMR (CD2Cl2, T = 213 K, 400 MHz,
H−H COSY, HSQC): δ 6.08 (d, 1H, J = 3.5 Hz, H-1), 5.59 (s, 1H,
CHPh), 4.89 (d, 1H, J = 11.0 Hz, CHH Bn), 4.85−4.69 (m, 3H, CHH
Bn, CH2 Bn), 4.29 (dd, 1H, J = 10.3, 4.8 Hz, H-6), 4.09−3.94 (m, 2H,
H-3, H-5), 3.86−3.70 (m, 3H, H-2, H-4, H-6). 13C-APT NMR
(CD2Cl2, T = 213 K, 101 MHz, HSQC): δ 106.1 (C-1), 100.8
(CHPh), 79.6 (C-4), 77.0 (C-3), 76.3 (C-2), 75.0, 74.1 (CH2 Bn),
67.4 (C-6), 65.8 (C-5).
Trifluoromethanesulfonyl 2-Azido-3-O-benzyl-4,6-O-benzyli-
dene-2-deoxy-α-D-glucopyranoside (20). 1H NMR (CD2Cl2, T =
243 K, 400 MHz, H−H COSY, HSQC): δ 6.08 (d, 1H, J = 3.5 Hz, H-
1), 5.64 (s, 1H, CHPh), 4.98 (d, 1H, J = 10.6 Hz, CHH Bn), 4.78 (d,
1H, J = 10.6 Hz, CHH Bn), 4.32 (dd, 1H, J = 10.4, 4.9 Hz, H-6),
4.11−4.00 (m, 2H, H-3, H-5), 3.94−3.86 (m, 2H, H-2, H-4), 3.82 (t,
1H, J = 10.3 Hz, H-6). 13C-APT NMR (CD2Cl2, T = 243 K, 101 MHz,
HSQC): δ 137.2, 136.7 (Cq), 130.5, 128.4, 128.4, 125.9 (CHarom),
105.0 (C-1), 101.3 (CHPh), 80.6 (C-4), 76.4 (C-3), 75.3 (CH2 Bn),
67.6 (C-6), 66.2 (C-5), 61.4 (C-2).
Trifluoromethanesulfonyl 2-Azido-3-O-benzoyl-4,6-O-benzyli-
dene-2-deoxy-α-D-glucopyranoside (21). 1H NMR (CD2Cl2, T =
243 K, 400 MHz, H−H COSY, HSQC): δ 6.23 (d, 1H, J = 3.5 Hz, H-
1), 5.80 (t, 1H, J = 10.0 Hz, H-3), 5.54 (s, 1H, CHPh), 4.36 (dd, 1H, J
= 10.4, 4.9 Hz, H-6), 4.21 (td, 1H, J = 9.9, 4.9 Hz, H-5), 4.12 (dd, 1H,
J = 10.2, 3.5 Hz, H-2), 3.98 (t, 1H, J = 9.8 Hz, H-4), 3.86 (t, 1H, J =
10.3 Hz, H-6). 13C-APT NMR (CD2Cl2, T = 243 K, 101 MHz,
HSQC): δ 104.5 (C-1), 101.8 (CHPh), 77.5 (C-4), 69.3 (C-3), 67.6
(C-6), 66.4 (C-5), 60.9 (C-2).
Trifluoromethanesulfonyl 2-Azido-3-O-benzyl-2-deoxy-4,6-O-di-
tert-butylsilylidene-α-D-glucopyranoside (22). 1H NMR (CD2Cl2, T
= 233 K, 400 MHz, H−H COSY, HSQC, HMBC): δ 6.00 (d, 1H, J =
3.4 Hz, H-1), 5.08 (d, 1H, J = 10.1 Hz, CHH Bn), 4.81 (d, 1H, J =
10.2 Hz, CHH Bn), 4.15−4.06 (m, 2H, H-4, H-6), 3.95−3.84 (m, 3H,
H-3, H-5, H-6), 3.79 (dd, 1H, J = 10.1, 3.4 Hz, H-2), 1.07 (s, 9H, CH3
tBu), 1.00 (s, 9H, CH3
tBu). 13C-APT NMR (CD2Cl2, T = 233 K, 101
MHz, HSQC, HMBC): δ 118.9 (q, J = 317.6 Hz, CF3), 104.8 (C-1),
78.8 (C-3), 76.9 (C-4), 75.7 (CH2 Bn), 70.0 (C-5), 65.3 (C-6), 60.6
(C-2), 27.0, 26.4 (CH3
tBu), 22.5, 19.7 (Cq
tBu). 13C-HMBC NMR
(CD2Cl2, 101 MHz): δ 104.8 (JC1−H1 = 187 Hz, C-1).
3-O-Benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyri-
done)-D-glucal (24). Off-white solid. Rf 0.20 (7:3 pentane/EtOAc).
[α]D
23 = +85.9° (c = 0.32, DCM). IR (thin film): 698, 720, 753, 1007,
1059, 1095, 1192, 1247, 1304, 1351, 1516, 1679, 2880, 2924, 3072. 1H
NMR (acetone-d6, 500 MHz, H−H COSY, HSQC): δ 8.72 (s, 2H,
CH pyridone), 7.62−7.53 (m, 2H, CHarom), 7.49−7.37 (m, 4H,
CHarom, H-1), 7.29−7.14 (m, 5H, CHarom), 5.88 (s, 1H, CHPh), 4.93−
4.88 (m, 2H, CHH Bn, H-3), 4.68 (d, 1H, J = 11.8 Hz, CHH Bn), 4.46
(dd, 1H, J = 10.5, 5.2 Hz, H-6), 4.37 (dd, 1H, J = 10.4, 6.9 Hz, H-4),
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4.30 (td, 1H, J = 10.2, 5.1 Hz, H-5), 4.03 (t, 1H, J = 10.3 Hz, H-6).
13C-APT NMR (acetone-d6, 101 MHz, HSQC): δ 160.0 (CO
pyridone), 149.3 (C-1), 144.7 (CH pyridone), 142.8 (Cq NO2), 138.4
(Cq Bn, Ph), 129.8, 129.2, 129.1, 129.0, 128.8, 127.0 (CHarom), 122.1
(C-2), 101.9 (CHPh), 80.2 (C-4), 74.7 (CH2 Bn), 74.6 (C-3), 70.7
(C-5), 68.2 (C-6). HRMS: [M + H]+ calcd for C25H22N3O9
508.13506, found 508.13465.
Ethyl 2-Azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-β-
D-glucopyranoside (2A). Donor 2 and ethanol were condensed using
the general procedure for Tf2O/Ph2SO-mediated glycosylations and
purified by flash column chromatography (0% to 5% Et2O in pentane)
to yield glycosylation product 2A (30 mg, 65 μmol, 65%, α/β < 1:20)
as a colorless oil. Rf 0.35 (5% Et2O in pentane). [α]D
23 = −69.6° (c =
0.5, CHCl3). IR (neat): 652, 768, 827, 962, 1082, 1161, 1474, 2112,
2859, 2932. 1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC): δ
7.46−7.40 (m, 2H, CHarom), 7.39−7.27 (m, 3H, CHarom), 4.99 (d, 1H,
J = 11.0 Hz, CHH Bn), 4.81 (d, 1H, J = 10.9 Hz, CHH Bn), 4.31 (dd,
1H, J = 7.7, 1.7 Hz, H-1), 4.16 (dd, 1H, J = 10.3, 5.0 Hz, H-6), 3.98−
3.87 (m, 3H, CHHCH3 Et, H-4, H-6), 3.61 (dq, 1H, J = 9.5, 7.1 Hz,
CHHCH3 Et), 3.41−3.28 (m, 3H, H-2, H-3, H-5), 1.26 (t, 3H, J =
7.1 Hz, CH3 Et), 1.08 (s, 9H, CH3
tBu), 1.01 (s, 9H, CH3
tBu). 13C-
APT NMR (CDCl3, 101 MHz, HSQC): δ 138.3 (Cq), 128.5, 128.4,
128.0 (CHarom), 102.1 (C-1), 82.4 (C-3), 78.1 (C-4), 75.4 (CH2 Bn),
70.5 (C-5), 66.4 (C-6), 66.1 (CH2 Et), 65.6 (C-2), 27.6, 27.2 (CH3
tBu), 22.8, 20.1 (Cq
tBu), 15.2 (CH3 Et). HRMS: [M − N2 + H]+
calcd for C23H38NO5Si 436.25138, found 436.25132.
Cyclohexyl 2-Azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilyli-
dene-β-D-glucopyranoside (2B). Donor 2 and cyclohexanol were
condensed using the general procedure for Tf2O/Ph2SO-mediated
glycosylations and purified by flash column chromatography (4:1 to
0:1 pentane/toluene) to yield glycosylation product 2B (40 mg, 77
μmol, 77%, α/β < 1:20) as a colorless oil. Rf 0.43 (5% Et2O in
pentane). [α]D
20 = −44.3° (c = 1.0, CHCl3). IR (thin film): 696, 768,
827, 961, 1080, 1163, 1364, 2112, 2859, 2934. 1H NMR (CDCl3, 400
MHz, H−H COSY, HSQC): δ 7.45−7.40 (m, 2H, CHarom), 7.38−7.27
(m, 3H, CHarom), 4.97 (d, 1H, J = 11.1 Hz, CHH Bn), 4.81 (d, 1H, J =
11.1 Hz, CHH Bn), 4.42 (d, 1H, J = 7.8 Hz, H-1), 4.15 (dd, 1H, J =
10.3, 5.0 Hz, H-6), 3.99−3.89 (m, 2H, H-3, H-6), 3.64 (tt, 2H, J = 9.2,
3.8 Hz, CH Cy), 3.40−3.24 (m, 3H, H-2, H-4, H-5), 1.96−1.83 (m,
2H, CH2 Cy), 1.80−1.71 (m, 2H, CH2 Cy), 1.55−1.48 (m, 1H, CH2
Cy), 1.47−1.37 (m, 2H, CH2 Cy), 1.34−1.20 (m, 3H, CH2 Cy), 1.08
(s, 9H, tBu), 1.01 (s, 9H, tBu). 13C-APT NMR (CDCl3, 101 MHz,
HSQC): δ 138.4 (Cq), 128.5, 128.3, 127.9 (CHarom), 100.7 (C-1), 82.3
(C-4), 78.3 (CH Cy), 78.0 (C-3), 75.4 (CH2 Bn), 70.5 (C-5), 66.4 (C-
6), 65.8 (C-2), 33.6, 31.7 (CH2 Cy), 27.6, 27.2 (CH3
tBu), 25.6 (CH2
Cy), 24.1, 23.9 (Cq tBu), 22.8, 20.1 (CH2 Cy). HRMS: [M − N2 +
H]+ calcd for C27H44NO5Si 490.29833, found 490.29811.
Methyl 6-O-(2-Azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilyli-
dene-α/β-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-glucopyranoside
(2C). Donor 2 and acceptor 25 were condensed using the general
procedure for Tf2O/Ph2SO-mediated glycosylations (for an additional
18 h at −40 °C) and purified by flash column chromatography (1:0 to
9:1 pentane/EtOAc) to yield glycosylation product 2C (81 mg, 92
μmol, 92%, α/β = 1:14) as a white solid. Rf 0.42 (4:1 pentane/
EtOAc). [α]D
23 = −18.6° (c = 1.0, CHCl3). IR (thin film): 654, 969,
735, 827, 962, 1028, 1070, 1161, 1362, 1454, 2112, 2859, 2931. 1H
NMR (CDCl3, 400 MHz, H−H COSY, HSQC, HMBC): δ 7.45−7.39
(m, 2H, CHarom), 7.38−7.25 (m, 18H, CHarom), 4.99 (d, 1H, J = 11.0
Hz, CHH Bn), 4.98 (d, 1H, J = 10.9 Hz, CHH Bn), 4.94 (d, 1H, J =
11.1 Hz, CHH Bn), 4.85−4.76 (m, 3H, CHH Bn, 2 × CHH Bn), 4.66
(d, 1H, J = 11.1 Hz, CHH Bn), 4.64 (d, 1H, J = 12.1 Hz, CHH Bn),
4.60 (d, 1H, J = 3.6 Hz, H-1), 4.17 (d, 1H, J = 7.9 Hz, H-1′), 4.15−
4.10 (m, 1H, H-6′), 4.05−3.96 (m, 2H, H-3, H-6), 3.96−3.87 (m, 2H,
H-4′, H-6′), 3.76 (ddd, 1H, J = 9.9, 4.2, 1.7 Hz, H-5), 3.70 (dd, 1H, J =
10.7, 4.2 Hz, H-6), 3.59 (t, 1H, J = 9.5 Hz, H-4), 3.54 (dd, 1H, J = 9.6,
3.5 Hz, H-2), 3.40 (dd, 1H, J = 9.7, 7.9 Hz, H-2′), 3.37−3.26 (m, 5H,
CH3 Ome, H-3′, H-5′), 1.07 (s, 9H, CH3 tBu), 1.01 (s, 9H, CH3 tBu).
13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 138.9, 138.6,
138.2, 138.1 (Cq), 128.6, 128.5, 128.5, 128.4, 128.3, 128.1, 128.0,
128.0, 127.9, 127.8, 127.7 (CHarom), 102.2 (C-1′), 98.3 (C-1), 82.5 (C-
3′), 82.2 (C-3), 79.9 (C-2), 77.9 (C-4′), 77.7 (C-4), 75.9, 75.4, 75.0,
73.6 (CH2 Bn), 70.6 (C-5′), 69.7 (C-5), 68.6 (C-6), 66.3 (C-6′), 65.6
(C-2′), 55.3 (OMe), 27.5, 27.1 (CH3 tBu), 22.8, 20.1 (Cq tBu).
Diagnostic peaks for the α-anomer: 1H NMR (CDCl3, 400 MHz): δ
4.87 (d, 1H, J = 3.6 Hz, H-1′), 4.52 (d, 1H, J = 3.4 Hz, H-1). 13C-APT
NMR (CDCl3, 101 MHz): δ 98.1, 98.0, 68.3. HRMS: [M + NH4]
+
calcd for C49H67N4O10Si 899.46210, found 899.46246.
2-Fluoroethyl 2-Azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsi-
lylidene-α/β-D-glucopyranoside (2D). Donor 2 and 2-fluoroethanol
were condensed using the general procedure for Tf2O/Ph2SO-
mediated glycosylations and purified by flash column chromatography
(1:0 to 0:1 pentane/toluene to 2% Et2O in toluene) to yield
glycosylation product 2D (37.8 mg, 79 μmol, 79%, α/β = 1:5.5) as a
colorless oil. Rf 0.20 (toluene). Data reported for a 1.00:0.18 mixture
of anomers: IR (neat): 654, 768, 827, 962, 1080, 1161, 1472, 2112,
2859, 2932. 1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC): δ
7.45−7.40 (m, 2.36H, CHarom), 7.39−7.27 (m, 3.54H, CHarom), 5.06
(d, 0.18H, J = 10.7 Hz, CHH Bnα), 4.99 (d, 1H, J = 10.9 Hz, CHH
Bnβ), 4.86 (d, 0.18H, J = 3.6 Hz, H-1α), 4.82 (d, 0.18H, J = 10.6 Hz,
CHH Bnα), 4.82 (d, 1H, J = 10.9 Hz, CHH Bnβ), 4.71−4.61 (m,
1.18H, CHHFα, CHHFβ), 4.58−4.47 (m, 1.18H, CHHFα, CHHFβ),
4.37 (d, 1H, J = 7.6 Hz, H-1β), 4.17 (dd, 1H, J = 10.3, 5.1 Hz, H-6β),
4.12−3.78 (m, 5.26H, CH2CH2Fα, CH2CH2Fβ, H-3α, H-4α, H-4β,
H-5α, H-6α, H-6α, H-6β), 3.44−3.29 (m, 3.18H, H-2α, H-2β, H-3β, H-
5β), 1.09 (s, 1.62H, CH3
tBuα), 1.08 (s, 9H, CH3
tBuβ), 1.03 (s, 1.62H
CH3
tBuα), 1.01 (s, 9H, CH3
tBuβ).
13C-APT NMR (CDCl3, 101
MHz, HSQC): δ 138.3 (Cq,α), 138.2 (Cq,β), 128.6 (CHarom Bnα), 128.5
(CHarom Bnβ), 128.5 (CHarom Bnα), 128.4 (CHarom Bnβ), 128.0
(CHarom Bnα,β), 102.4 (C-1β), 98.3 (C-1α), 82.7 (d, J = 170.0 Hz,
CH2Fβ), 82.4 (d, J = 170.6 Hz, CH2Fα), 82.3 (C-3β), 79.3, 79.0 (C-3α,
C-4α), 78.0 (C-4β), 75.6 (CH2 Bnα), 75.5 (CH2 Bnβ), 70.6 (C-5β),
69.0 (d, J = 20.3 Hz, CH2CH2Fβ), 67.3 (d, J = 20.1 Hz, CH2
CH2Fα), 66.8 (C-5α), 66.7 (C-6α), 66.3 (C-6β), 65.5 (C-2β), 62.5 (C-





tBuβ). HRMS: [M − N2 + H]+ calcd for
C23H37FNO5Si 454.24195, found 454.24188.
Methyl 4-O-(2-Azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilyli-
dene-α/β-D-glucopyranosyl)-2,3,6-tri-O-benzyl-α-D-glucopyranoside
(2E). Donor 2 and acceptor 26 were condensed using the general
procedure for Tf2O/Ph2SO-mediated glycosylations (for an additional
18 h at −40 °C) and purified by flash column chromatography (1:0 to
9:1 pentane/EtOAc) to yield glycosylation product 2E (72 mg, 82
μmol, 82%, α/β = 1:3) as a colorless oil. Rf 0.23 and 0.41 (9:1
pentane/EtOAc). IR (thin film): 654, 696, 735, 768, 827, 962, 1090,
1159, 1271, 1362, 1454, 2110, 2859, 2932. Data for the β-anomer: 1H
NMR (CDCl3, 400 MHz, H−H COSY, HSQC, HMBC): δ 7.44−7.39
(m, 2H, CHarom), 7.39−7.21 (m, 18H, CHarom), 4.98 (d, 1H, J = 10.8
Hz, CHH Bn), 4.83−4.74 (m, 4H, CHH Bn, CH2 Bn, CHH Bn), 4.68
(d, 1H, J = 11.9 Hz, CHH Bn), 4.62 (d, 1H, J = 12.2 Hz, CHH Bn)
4.59 (d, 1H, J = 3.6 Hz, H-1), 4.44 (d, 1H, J = 11.9 Hz, CHH Bn),
4.23 (d, 1H, J = 8.0 Hz, H-1′), 3.97 (dd, 1H, J = 10.6, 3.0 Hz, H-6),
3.94−3.73 (m, 5H, H-3, H-4, H-4′, H-5, H-6′), 3.71−3.66 (m, 1H, H-
6), 3.55−3.47 (m, 2H, H-2, H-6′), 3.38 (s, 3H, CH3 OMe), 3.27−3.21
(m, 1H, H-2′), 3.20−3.14 (m, 1H, H-3′), 3.06 (td, 1H, J = 9.9, 5.1 Hz,
H-5′), 1.06 (s, 9H, CH3 tBu), 0.97 (s, 9H, CH3 tBu). 13C-APT NMR
(CDCl3, 101 MHz, HSQC, HMBC): δ 139.4, 138.4, 138.1, 137.9
(Cq), 128.5, 128.5, 128.5, 128.4, 128.4, 128.2, 128.1, 128.0, 128.0,
127.9, 127.4, 127.3 (CHarom), 101.0 (C-1′), 98.4 (C-1), 82.6 (C-3′),
80.2 (C-3), 79.2 (C-2), 78.1 (C-4′), 77.0 (C-4), 75.3, 75.3, 73.6, 73.6
(CH2 Bn), 70.2 (C-5′), 69.7 (C-5), 68.3 (C-6), 66.2 (C-6′), 66.1 (C-
2′), 55.4 (OMe), 27.6, 27.1 (CH3 tBu), 22.7, 20.0 (Cq tBu). Diagnostic
peaks for the α-anomer: 1H NMR (CDCl3, 400 MHz): δ 5.67 (d, 1H,
J = 4.0 Hz, H-1), 5.11 (d, 1H, J = 10.6 Hz, CHH Bn), 5.06 (d, 1H, J =
10.6 Hz, CHH Bn), 4.87 (d, 1H, J = 10.6 Hz, CHH Bn), 4.79 (d, 1H, J
= 10.6 Hz, CHH Bn), 4.75 (d, 1H, J = 12.0 Hz, CHH Bn), 4.09 (t, 1H,
J = 9.0 Hz, H-3), 3.56 (dd, 1H, J = 9.6, 3.5 Hz, H-2), 3.38 (s, CH3
OMe), 3.21 (dd, 1H, J = 10.2, 4.0 Hz, H-2′), 1.06 (s, 9H, CH3 tBu),
1.04 (s, 9H, CH3
tBu). 13C-APT NMR (CDCl3, 101 MHz): δ 138.8,
138.3, 138.2, 138.0, 128.6, 128.4, 128.3, 128.1, 128.0, 128.0, 128.0,
127.9, 127.7, 127.6, 127.4, 127.3, 97.9, 97.7 (C-1, C-1′), 82.1 (C-3),
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80.6 (C-2), 79.1, 79.0, 75.6, 75.1, 73.7, 73.4, 69.6, 69.2, 67.5, 66.5, 62.3
(C-2′), 55.4, 27.6, 27.2, 22.8, 20.1. HRMS: [M + NH4]+ calcd for
C49H67N4O10Si 899.46210, found 899.46246.
Methyl (Methyl 4-O-[2-Azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-
butylsilylidene-α/β-D-glucopyranosyl]-2,3-di-O-benzyl-α-D-gluco-
pyranosyl uronate) (2F). Donor 2 and acceptor 27 were condensed
using the general procedure for Tf2O/Ph2SO-mediated glycosylations
(for an additional 18 h at −40 °C) and purified by flash column
chromatography (1:0 to 9:1 pentane/EtOAc) to yield glycosylation
product 2F (69 mg, 84 μmol, 84%, α/β = 3.3:1) as a white solid. Rf
0.36 and 0.39 (9:1 pentane/EtOAc). IR (thin film): 654, 696, 735,
827, 1042, 1144, 1387, 1751, 2108, 2859, 2934. Data for the α-
anomer: 1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC, HMBC):
δ 7.43−7.38 (m, 2H, CHarom), 7.37−7.25 (m, 13H, CHarom), 5.45 (d,
1H, J = 4.1 Hz, H-1′), 5.07−5.02 (m, 2H, 2 × CHH Bn), 4.90 (d, 1H,
J = 10.6 Hz, CHH Bn), 4.84−4.78 (m, 1H, CHH Bn), 4.75 (d, 1H, J =
12.0 Hz, CHH Bn), 4.59 (d, 1H, J = 12.2 Hz, CHH Bn), 4.57 (d, 1H, J
= 3.5 Hz, H-1), 4.21−4.17 (m, 1H, H-5), 4.09−4.01 (m, 3H, H-3, H-4,
H-6′), 3.91−3.85 (m, 1H, H-4′), 3.83−3.73 (m, 5H, CH3 CO2Me, H-
3′, H-6′), 3.62 (td, 1H, J = 10.1, 5.0 Hz, H-5′), 3.58−3.53 (m, 1H, H-
2), 3.41 (s, 3H, CH3 OMe), 3.23 (dd, 1H, J = 10.2, 4.1 Hz, H-2′), 1.07
(s, 9H, CH3
tBu), 1.05 (s, 9H, CH3
tBu). 13C-APT NMR (CDCl3, 101
MHz, HSQC, HMBC): δ 169.2 (CO CO2Me), 138.7, 138.2, 137.8
(Cq), 128.7, 128.5, 128.5, 128.5, 128.3, 128.2, 128.0, 127.7, 127.6
(CHarom), 98.5, 98.4 (C-1, C-1′), 81.0 (C-3), 79.9 (C-2), 79.0, 79.0
(C-3′, C-4′), 76.2 (C-4), 75.5, 75.4, 73.6 (CH2 Bn), 70.2 (C-5), 67.0
(C-5′), 66.4 (C-6′), 62.4 (C-2′), 55.9 (OMe), 52.9 (CO2Me), 27.6,
27.2 (CH3
tBu), 22.9, 20.0 (Cq
tBu). Diagnostic peaks for the β-
anomer: 1H NMR (CDCl3, 400 MHz): δ 4.98 (d, 1H, J = 10.9 Hz,
CHH Bn), 4.39 (d, 1H, J = 7.7 Hz, H-1′), 4.02−3.96 (m, 1H), 3.82 (s,
3H, CH3 CO2Me), 3.52 (dd, 1H, J = 9.5, 3.6 Hz, H-2), 1.05 (s, 9H,
CH3
tBu), 0.97 (s, 9H, CH3,
tBu). 13C-APT NMR (CDCl3, 101
MHz): δ 170.2, 139.1, 138.1, 138.1, 128.6, 128.5, 128.4, 128.3, 128.3,
128.1, 128.0, 127.5, 127.3, 101.9 (C-1′), 98.9 (C-1), 82.5, 79.6, 79.4,
78.8, 78.0, 75.4, 73.9, 70.4, 69.9, 66.1, 55.9, 52.8, 27.5, 27.1, 22.8, 20.0.
HRMS: [M + NH4]
+ calcd for C43H61N4O11Si 837.41006, found
837.41042.
2,2-Difluoroethyl 2-Azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-bu-
tylsilylidene-α/β-D-glucopyranoside (2G). Donor 2 and 2,2-difluor-
oethanol were condensed using the general procedure for Tf2O/
Ph2SO-mediated glycosylations and purified by flash column
chromatography (1:0 to 0:1 pentane/toluene to 2% Et2O in toluene)
to yield glycosylation product 2G (38.1 mg, 76 μmol, 76%, α/β =
2.7:1) in two fractions (24.3 mg of α only, 13.8 mg of α/β = 0.3:1) as
white solids. Rf 0.43 β, 0.31 α (toluene). IR (neat): 654, 766, 826,
1070, 1474, 2108, 2860, 2934. Data for the α-anomer: [α]D
23 = +35.6°
(c = 0.86, CHCl3).
1H NMR (CDCl3, 400 MHz, H−H COSY,
HSQC): δ 7.45−7.40 (m, 2H, CHarom), 7.39−7.27 (m, 3H, CHarom),
5.95 (tt, 1H, J = 55.2, 4.1 Hz, CHF2), 5.06 (d, 1H, J = 10.6 Hz, CHH
Bn), 4.85 (d, 1H, J = 3.6 Hz, H-1), 4.82 (d, 1H, J = 10.7 Hz, CHH
Bn), 4.13−4.08 (m, 1H, H-6), 3.98−3.92 (m, 1H, H-3/4), 3.92−3.72
(m, 5H, CH2CHF2, H-3/4, H-5, H-6), 3.35 (dd, 1H, J = 10.1, 3.6
Hz, H-2), 1.09 (s, 9H, CH3
tBu), 1.03 (s, 9H, CH3
tBu). 13C-APT
NMR (CDCl3, 101 MHz, HSQC): δ 138.1 (Cq), 128.6, 128.5, 128.1
(CHarom), 113.8 (t, J = 241.6 Hz, CHF2), 98.7 (C-1), 79.0, 78.9 (C-3,
C-4), 75.7 (CH2 Bn), 67.3 (t, J = 28.6 Hz, CH2CHF2), 67.1 (C-5),
66.6 (C-6), 62.4 (C-2), 27.5, 27.1 (CH3
tBu), 22.8, 20.1 (Cq
tBu).
Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, H−H COSY,
HSQC): δ 7.44−7.39 (m, 2H, CHarom), 7.38−7.29 (m, 3H, CHarom),
5.92 (tdd, 1H, J = 55.3, 5.1, 3.4 Hz, CHF2), 4.99 (d, 1H, J = 10.9 Hz,
CHH Bn), 4.81 (d, 1H, J = 11.0 Hz, CHH Bn), 4.35 (s, 1H, J = 7.7 Hz,
H-1), 4.17 (dd, 1H, J = 10.3, 5.0 Hz, H-6), 4.02−3.74 (m, 4H, CH2
CHF2, H-4, H-6), 3.42−3.30 (m, 3H, H-2, H-3, H-5), 1.09 (s, 9H,
CH3
tBu), 1.01 (s, 9H, CH3,
tBu). 13C-APT NMR (CDCl3, 101 MHz,
HSQC): δ 138.1 (Cq), 128.5, 128.4, 128.1 (CHarom), 114.1 (t, J =
241.4 Hz, CHF2), 102.5 (C-1), 82.2 (C-3), 77.9 (C-4), 75.5 (CH2
Bn), 70.7 (C-5), 68.8 (dd, J = 29.3, 28.8 Hz, CH2CHF2), 66.2 (C-
6), 65.4 (C-2), 27.5, 27.1 (CH3
tBu), 22.8, 20.1 (Cq
tBu). HRMS: [M
− N2 + H]+ calcd for C23H36F2NO5Si 472.23253, found 472.23239.
Methyl 4-O-(2-Azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilyli-
dene-α/β-D-glucopyranosyl)-2,3,6-tri-O-benzyl-β-D-galactopyrano-
side (2H). Donor 2 and acceptor 28 were condensed using the general
procedure for Tf2O/Ph2SO-mediated glycosylations (for an additional
18 h at −40 °C) and purified by flash column chromatography (1:0 to
9:1 pentane/EtOAc) to yield glycosylation product 2H (46 mg, 52
μmol, 52%, α/β = 7:1) as a colorless oil. Rf 0.33 and 0.51 (9:1
pentane/EtOAc). IR (thin film): 652, 696, 735, 826, 1001, 1036, 1206,
1364, 1454, 2108, 2859, 2932. Data for the α-anomer: 1H NMR
(CDCl3, 400 MHz, H−H COSY, HSQC, HMBC): δ 7.46−7.41 (m,
2H, CHarom), 7.41−7.23 (m, 18H, CHarom), 5.10 (d, 1H, J = 10.3 Hz,
CHH Bn), 4.89−4.81 (m, 3H, CHH Bn, 2 × CHH Bn), 4.79 (d, 1H, J
= 3.7 Hz, H-1′), 4.72 (d, 1H, J = 10.6 Hz, CHH Bn), 4.68 (d, 1H, J =
13.0 Hz, CHH Bn), 4.58−4.44 (m, 3H, CH2 Bn, H-5′), 4.23 (d, 1H, J
= 7.6 Hz, H-1), 4.07−3.99 (m, 2H, H-4, H-6), 3.99−3.88 (m, 3H, H-
3′, H-4′, H-6′), 3.76 (t, 1H, J = 10.1 Hz, H-6′), 3.67−3.58 (m, 2H, H-
2, H-6), 3.56 (s, 3H, CH3 OMe), 3.48 (dd, 1H, J = 8.9, 5.5 Hz, H-5),
3.38 (dd, 1H, J = 10.0, 2.9 Hz, H-3), 3.33 (dd, 1H, J = 9.7, 3.7 Hz, H-
2′), 1.06 (s, 9H, CH3 tBu), 1.02 (s, 9H, CH3 tBu). 13C-APT NMR
(CDCl3, 101 MHz, HSQC, HMBC): δ 138.8, 138.4, 138.2, 137.7
(Cq), 128.6, 128.6, 128.5, 128.5, 128.5, 128.3, 128.2, 127.9, 127.8
(CHarom), 105.1 (C-1), 99.2 (C-1′), 79.9, 79.9 (C-2, C-3′), 79.6, 79.4
(C-3, C-4′), 75.7, 75.6 (CH2 Bn), 75.0 (C-4), 73.6 (CH2 Bn), 72.9 (C-
5), 72.6 (CH2 Bn), 67.1, 67.0 (C-6, C-6′), 66.9 (C-5′), 63.2 (C-2′),
57.5 (OMe), 27.5, 27.3 (CH3
tBu), 22.7, 20.2 (Cq
tBu). Diagnostic
peaks for the β-anomer: 1H NMR (CDCl3, 400 MHz): δ 4.94 (d,
0.14H, J = 11.1 Hz, CHH Bn), 4.27 (d, 0.14H, J = 7.7 Hz, H-1), 3.22−
3.16 (m, 0.28H), 3.20−3.09 (m, 2H). 13C-APT NMR (CDCl3, 101
MHz): δ 105.1 (C-1), 102.0 (C-1′), 82.3, 78.0, 75.4, 75.3, 73.7, 73.7,
73.5, 73.4, 70.4, 69.6, 66.4, 65.6, 57.3, 27.6, 27.2, 22.8, 20.1. HRMS:
[M + NH4]
+ calcd for C49H67N4O10Si 899.46210, found 899.46243.
Methyl 2-O-(2-Azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilyli-
dene-α-D-glucopyranosyl)-3-O-benzyl-4,6-O-benzylidene-α-D-man-
nopyranoside (2I). Donor 2 and acceptor 29 were condensed using
the general procedure for Tf2O/Ph2SO-mediated glycosylations (for
an additional 18 h at −40 °C) and purified by flash column
chromatography (1:0 to 9:1 pentane/EtOAc) to yield glycosylation
product 2I (67 mg, 85 μmol, 85%, α/β > 20:1) as a white solid. Rf 0.54
(9:1 pentane/EtOAc). [α]D
20 = +44.3° (c = 1.34, CHCl3). IR (thin
film): 696, 827, 937, 1040, 1088, 1130, 1364, 2108, 2859, 2957. Data
for the α-anomer: 1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC,
HMBC): δ 7.54−7.47 (m, 2H, CHarom), 7.46−7.41 (m, 2H, CHarom),
7.41−7.22 (m, 11H, CHarom), 5.65 (s, 1H, CHPh), 5.23 (d, 1H, J = 3.6
Hz, H-1′), 5.09 (d, 1H, J = 10.6 Hz, CHH Bn), 4.89−4.82 (m, 2H,
CHH Bn, CHH Bn), 4.74−4.65 (m, 2H, CHH Bn, H-1), 4.31−4.21
(m, 2H, H-4, H-6), 4.11−3.92 (m, 5H, H-2, H-3, H-3′, H-4′, H-6′),
3.92−3.76 (m, 4H, H-5, H-5′, H-6, H-6′), 3.36 (s, 3H, CH3 OMe),
3.27 (dd, 1H, J = 10.0, 3.7 Hz, H-2′), 1.09 (s, 9H), 1.05 (s, 9H). 13C-
APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 138.6, 138.4, 137.7
(Cq), 129.0, 128.5, 128.5, 128.4, 128.3, 128.3, 128.0, 127.6, 127.5,
127.4, 126.2, 126.1 (CHarom), 101.7 (CHPh), 101.0 (C-1), 99.4 (C-
1′), 79.3 (C-4), 79.1, 78.9 (C-3′, C-4′), 76.0, 75.6 (C-2, C-3), 75.6,
73.0 (CH2 Bn), 69.0 (C-6), 67.2 (C-5′), 66.6 (C-6′), 64.1 (C-5), 62.6
(C-2′), 55.2 (CH3 OMe), 27.5, 27.2 (CH3 tBu), 22.8, 20.2 (Cq tBu).
Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 400 MHz): δ
5.60 (s, 1H, CHPh), 4.98 (d, 1H, J = 11.3 Hz, CHH Bn), 4.39 (d, 1H,
J = 8.2 Hz, H-1′), 3.57−3.48 (m, 1H). 13C-APT NMR (CDCl3, 101
MHz): δ 101.6, 99.6, 81.8, 78.5, 77.8, 76.4, 75.2, 74.4, 72.3, 70.9, 65.7,
55.1, 27.5, 27.1. HRMS: [M + NH4]
+ calcd for C42H59N4O10Si
807.39950, found 807.39931.
2,2,2-Trifluoroethyl 2-Azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-
butylsilylidene-α-D-glucopyranoside (2J). Donor 2 and 2,2,2-
trifluoroethanol were condensed using the general procedure for
Tf2O/Ph2SO-mediated glycosylations (for an additional 30 min at −40
°C) and purified by flash column chromatography (1:0 to 0:1
pentane/toluene to 2% Et2O in toluene) to yield glycosylation product
2J (42.4 mg, 82 μmol, 82%, α/β > 20:1) as a colorless oil. Rf 0.36
(toluene). [α]D
23 = +32.6° (c = 1.0, CHCl3). IR (neat): 654, 766, 826,
1036, 1082, 1159, 1279, 1472, 2108, 2859, 2930. 1H NMR (CDCl3,
400 MHz, H−H COSY, HSQC): δ 7.45−7.39 (m, 2H, CHarom),
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7.38−7.27 (m, 3H, CHarom), 5.07 (d, 1H, J = 10.6 Hz, CHH Bn), 4.88
(d, 1H, J = 3.6 Hz, H-1), 4.82 (d, 1H, J = 10.6 Hz, CHH Bn), 4.14−
4.07 (m, 1H, H-6), 4.03−3.93 (m, 3H, CH2CF3, H-4), 3.92−3.80
(m, 3H, H-3, H-5, H-6), 3.36 (dd, 1H, J = 10.0, 3.6 Hz, H-2), 1.09 (s,
9H, CH3
tBu), 1.03 (s, 9H, CH3
tBu). 13C-APT NMR (CDCl3, 101
MHz, HSQC): δ 138.1 (Cq), 128.6, 128.5, 128.1 (CHarom), δ 123.5 (q,
J = 278.4 Hz, CF3), 98.8 (C-1), 78.9 (C-3), 78.8 (C-4), 75.7 (CH2
Bn), 67.4 (C-5), 66.5 (C-6), 65.2 (q, J = 35.4 Hz, CH2CF3), 62.2
(C-2), 27.5, 27.1 (CH3
tBu), 22.8, 20.1 (Cq
tBu). HRMS: [M − N2 +
H]+ calcd for C23H35F3NO5Si 490.22311, found 490.22292.
1,1,1,3,3,3-Hexafluoro-2-propyl 2-azido-3-O-benzyl-2-deoxy-4,6-
O-di-tert-butylsilylidene-α-D-glucopyranoside (2K). Donor 2 and
1,1,1,3,3,3-hexafluoro-2-propanol were condensed using the general
procedure for Tf2O/Ph2SO-mediated glycosylations (for an additional
72 h at −40 °C) and purified by flash column chromatography (4:1 to
0:1 pentane/toluene) to yield glycosylation product 2K (20 mg, 34
μmol, 34%, α/β > 20:1) as a white solid. Rf 0.38 (9:1 pentane/Et2O).
[α]D
20 = +31.2° (c = 0.50, CHCl3). IR (thin film): 689, 827, 1030, 1098,
1221, 1288, 1368, 2112, 2860, 2934. 1H NMR (CDCl3, 400 MHz, H−
H COSY, HSQC, HMBC, NOESY): δ 7.45−7.28 (m, 5H, CHarom),
5.12−5.04 (m, 2H, CHH Bn, H-1), 4.83 (d, 1H, J = 10.5 Hz, CHH
Bn), 4.40 (hept, 1H, J = 5.7 Hz, CH HFIP), 4.09 (dd, 1H, J = 9.4, 4.0
Hz, H-6), 4.03−3.91 (m, 2H, H-4, H-5), 3.91−3.83 (m, 2H, H-3, H-
6), 3.42 (dd, 1H, J = 10.2, 3.8 Hz, H-2), 1.08 (s, 9H, CH3
tBu), 1.03 (s,
9H, CH3
tBu). 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ
138.0 (Cq), 128.6, 128.5, 128.2 (CHarom), 100.4 (C-1), 78.7 (C-3),
78.4 (C-4), 75.8 (CH2 Bn), 73.3 (p, J = 33.2 Hz), 68.1 (C-5), 66.1 (C-
6), 61.9 (C-2), 27.5, 27.0 (CH3
tBu), 22.8, 20.1 (Cq
tBu). HRMS: [M
− N2 + H]+ calcd for C24H34F6NO5Si 558.21050, found 558.21009.
Ethyl 2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-β-D-gluco-
pyranoside (3A). Donor 3 and ethanol were condensed using the
general procedure for Tf2O/Ph2SO-mediated glycosylations and
purified by flash column chromatography (1:0 to 0:1 hexane/toluene
to 5% EtOAc in toluene) to yield glycosylation product 3A (34.3 mg,
83 μmol, 83%, α/β < 1:20) as a white solid. Rf 0.58 (9:1 toluene/
EtOAc). [α]D
23 = −79.6° (c = 0.69, CHCl3). IR (neat): 692, 993, 1098,
1186, 1267, 1365, 1452, 2111, 2878, 2979. 1H NMR (CDCl3, 400
MHz, H−H COSY, HSQC): δ 7.50−7.46 (m, 2H, CHarom), 7.41−7.28
(m, 8H, CHarom), 5.57 (s, 1H, CHPh), 4.91 (d, 1H, J = 11.2 Hz, CHH
Bn), 4.79 (d, 1H, J = 11.3 Hz, CHH Bn), 4.37 (d, 1H, J = 8.2 Hz, H-
1), 4.34 (dd, 1H, J = 10.6, 5.0 Hz, H-6), 3.96 (dq, 1H, J = 9.7, 7.1 Hz,
CHH Et), 3.80 (t, 1H, J = 10.3 Hz, H-6), 3.70 (t, 1H, J = 9.0 Hz, H-4),
3.66 (dq, 1H, J = 9.7, 7.2 Hz, CHH Et), 3.54 (t, 1H, J = 9.3 Hz, H-3),
3.44 (dd, 1H, J = 9.5, 8.0 Hz, H-2), 3.39 (td, 2H, J = 9.8, 5.0 Hz, H-5),
1.29 (t, 3H, J = 7.1 Hz, CH3 Et).
13C-APT NMR (CDCl3, 101 MHz,
HSQC): δ 138.0, 137.2 (Cq), 129.2, 128.5, 128.4, 128.3, 128.0, 126.1
(CHarom), 102.5 (C-1), 101.4 (CHPh), 81.7 (C-4), 79.1 (C-3), 75.0
(CH2 Bn), 68.7 (C-6), 66.3 (CH2 Et), 66.3, 66.2 (C-2, C-5), 15.2
(CH3 Et).
13C-HMBC-GATED NMR (CDCl3, 101 MHz): δ 102.5
(JC1,H1 = 161 Hz, C-1). HRMS: [M + NH4]
+ calcd for C22H29N4O5
429.21325, found 429.21321.
Cyclohexyl 2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-β-D-
glucopyranoside (3B). Donor 3 and cyclohexanol were condensed
using the general procedure for Tf2O/Ph2SO-mediated glycosylations
and purified by flash column chromatography (1:1 to 0:1 hexane/
toluene to 5% EtOAc in toluene) to yield glycosylation product 3B
(43 mg, 93 μmol, 93%, α/β < 1:20) as a white solid. Rf 0.23 (toluene).
[α]D
23 = −60.5° (c = 0.86, DCM). IR (neat): 696, 748, 998, 1092, 1275,
1365, 1452, 2108, 2858, 2933. Data for the β-anomer: 1H NMR
(CDCl3, 400 MHz, H−H COSY, HSQC): δ 7.50−7.44 (m, 2H,
CHarom), 7.42−7.27 (m, 8H, CHarom), 5.56 (s, 1H, CHPh), 4.90 (d,
1H, J = 11.4 Hz, CHH Bn), 4.79 (d, 1H, J = 11.4 Hz, CHH Bn), 4.47
(d, 1H, J = 7.8 Hz, H-1), 4.32 (dd, 1H, J = 10.5, 5.0 Hz, H-6), 3.79 (t,
1H, J = 10.3 Hz, H-6), 3.74−3.64 (m, 2H, H-4, CH Cyc), 3.50 (t, 1H,
J = 9.2 Hz, H-3), 3.44 (dd, 1H, J = 9.6, 7.8 Hz, H-2), 3.36 (td, 1H, J =
9.7, 5.0 Hz, H-5), 1.99−1.87 (m, 2H, CH2 Cyc), 1.82−1.72 (m, 2H, J
= 15.2, 4.4 Hz, CH2 Cyc), 1.56−1.37 (m, 3H, CH2 Cyc), 1.36−1.20
(m, 3H, CH2 Cyc).
13C-APT NMR (CDCl3, 101 MHz, HSQC): δ
138.0, 137.3 (Cq), 129.1, 128.5, 128.4, 128.3, 127.9, 126.1 (CHarom),
101.4 (CHPh), 101.0 (C-1), 81.6 (C-4), 79.0 (C-3), 78.5 (CH Cyc),
75.0 (CH2 Bn), 68.8 (C-6), 66.5 (C-2), 66.3 (C-5), 33.6, 31.8, 25.6,
24.1, 23.9 (CH2 Cyc). Diagnostic peaks for the α-anomer:
1H NMR
(CDCl3, 400 MHz): δ 5.59 (s, 0.04H, CHPh), 5.03 (d, 0.04H, J = 3.7
Hz, H-1), 4.12 (t, 0.04H, J = 9.5 Hz, H-3), 4.00 (td, 0.04H, J = 9.9, 4.8
Hz, H-5), 3.28 (dd, 0.04H, J = 10.0, 3.7 Hz, H-2). 13C-APT NMR
(CDCl3, 101 MHz): δ 101.4 (CHPh), 97.1 (C-1), 76.0 (C-3), 63.8
(C-2), 62.9 (C-5). HRMS: [M + NH4]




Donor 3 and acceptor 25 were condensed using the general procedure
for Tf2O/Ph2SO-mediated glycosylations (for an additional 18 h at
−40 °C) and purified by flash column chromatography (19:1 to 4:1
pentane/EtOAc) to yield glycosylation product 3C (73.7 mg, 89 μmol,
89%, α/β < 1:20) as a white solid. Rf 0.42 (4:1 pentane/EtOAc).
Spectroscopic data were in accord with those reported previously.38
[α]D
23 = −32.2° (c = 1.0, CHCl3). IR (neat): 696, 737, 999, 1028, 1070,
1090, 1277, 1362, 1497, 2108, 2876, 2926. 1H NMR (CDCl3, 400
MHz, H−H COSY, HSQC, HMBC): δ 7.47 (dd, 2H, J = 7.3, 2.5 Hz,
CHarom), 7.42−7.25 (m, 23H, CHarom), 5.55 (s, 1H, CHPh), 4.99 (d,
1H, J = 10.9 Hz, CHH 3-OBn), 4.95 (d, 1H, J = 11.2 Hz, CHH 4-
OBn), 4.91 (d, 1H, J = 11.2 Hz, CHH 3′-OBn), 4.85−4.76 (m, 3H,
CHH 3-OBn, CHH 2-OBn, CHH 3′-OBn), 4.70−4.63 (m, 2H, CHH
4-OBn, CHH 2-OBn), 4.61 (d, 1H, J = 3.6 Hz, H-1), 4.30 (dd, 1H, J =
10.5, 5.0 Hz, H-6′), 4.23 (d, 1H, J = 7.9 Hz, H-1′), 4.07 (d, 1H, J = 8.9
Hz, H-6), 4.00 (t, 1H, J = 9.3 Hz, H-3), 3.81−3.72 (m, 3H, H-5, H-6,
H-6′), 3.69 (t, 1H, J = 9.1 Hz, H-4′), 3.60 (t, 1H, J = 9.3 Hz, H-4),
3.59−3.46 (m, 3H, H-2, H-2′, H-3′), 3.37 (s, 3H, CH3 OMe), 3.36−
3.29 (m, 1H, H-5′). 13C-APT NMR (CDCl3, 101 MHz, HSQC,
HMBC): δ 138.8, 138.5, 138.2, 137.8, 137.2 (Cq), 129.2, 128.6, 128.5,
128.5, 128.4, 128.3, 128.3, 128.1, 128.1, 128.0, 127.9, 127.9, 127.7,
126.1 (CHarom), 102.4 (C-1′), 101.4 (CHPh), 98.4 (C-1), 82.2 (C-3),
81.5 (C-4′), 79.8 (C-2), 79.3 (C-3′), 77.6 (C-4), 75.9 (CH2 3-OBn),
75.0, 75.0 (CH2 3′-OBn, 4-OBn), 73.6 (CH2 2-OBn), 69.6 (C-5),
68.7, 68.6 (C-6, C-6′), 66.3 (C-5′), 66.1 (C-2′), 55.4 (OMe). HRMS:
[M + NH4]
+ calcd for C48H55N4O10 847.39127, found 847.39224.
2-Fluoroethyl 2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/
β-D-glucopyranoside (3D). Donor 3 and 2-fluoroethanol were
condensed using the general procedure for Tf2O/Ph2SO-mediated
glycosylations and purified by flash column chromatography (1:0 to
0:1 pentane/toluene to 5% EtOAc in toluene) to yield glycosylation
product 3D (38.5 mg, 90 μmol, 90%, α/β = 1:6.7) as a white solid. Rf
0.40 (19:1 toluene/EtOAc). IR (neat): 696, 748, 996, 1028, 1072,
1091, 1174, 1276, 1368, 1454, 2108, 2873, 2917. Data for the β-
anomer: 1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC): δ 7.50−
7.46 (m, 2H, CHarom), 7.41−7.36 (m, 5H, CHarom), 7.36−7.25 (m, 3H,
CHarom), 5.57 (s, 1H, CHPh), 4.91 (d, 1H, J = 11.2 Hz, CHH Bn),
4.79 (d, 1H, J = 11.3 Hz, CHH Bn), 4.69−4.64 (m, 1H, CHHF), 4.55
(dt, 1H, J = 4.6, 2.9 Hz, CHHF), 4.42 (d, 1H, J = 7.9 Hz, H-1), 4.34
(dd, 1H, J = 10.5, 5.0 Hz, H-6), 4.11 (ddd, 0.5H, J = 12.2, 4.8, 2.9 Hz,
CHHCFH2), 4.03 (ddd, 0.5H, J = 12.2, 4.7, 3.0 Hz, CHHCFH2),
3.92 (ddd, 0.5H, J = 12.2, 5.9, 3.2 Hz, CHHCFH2), 3.86 (ddd,
0.5H, J = 12.2, 6.0, 3.3 Hz, CHHCFH2), 3.80 (t, 1H, J = 10.3 Hz,
H-6), 3.71 (t, 1H, J = 9.2 Hz, H-4), 3.56 (t, 1H, J = 9.2 Hz, H-3), 3.48
(dd, 1H, J = 9.5, 7.9 Hz, H-2), 3.39 (td, 1H, J = 9.7, 4.9 Hz, H-5). 13C-
APT NMR (CDCl3, 101 MHz, HSQC): δ 137.8, 137.1 (Cq), 129.2,
128.5, 128.4, 128.3, 128.0, 126.1 (CHarom), 102.7 (C-1), 101.4
(CHPh), 82.6 (d, J = 170.1 Hz, CFH2), 81.5 (C-4), 79.0 (C-3), 75.1
(CH2 Bn), 69.3 (d, J = 20.1 Hz, CH2CFH2), 68.6 (C-6), 66.3 (C-5),
66.1 (C-2). 13C-HMBC-GATED NMR (CDCl3, 101 MHz): δ 102.7
(JC1,H1 = 162 Hz, C-1). Diagnostic peaks for the α-anomer:
1H NMR
(CDCl3, 400 MHz, H−H COSY, HSQC): δ 5.58 (s, 0.15H, CHPh),
4.96 (d, 0.15H, J = 10.9 Hz, CHH Bn), 4.95 (d, 0.15H, J = 3.7 Hz, H-
1), 4.81 (d, 0.15H, J = 11.0 Hz, CHH Bn), 4.29 (dd, 0.15H, J = 10.2,
4.9 Hz, H-6). 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 101.5
(CHPh), 98.8 (C-1), 82.8 (C-4), 76.2 (C-3), 75.2 (CH2 Bn), 68.9 (C-
6), 63.0, 62.9 (C-2, C-5). 13C-HMBC-GATED NMR (CDCl3, 101
MHz): δ 98.8 (JC1,H1 = 172 Hz, C-1). HRMS: [M + NH4]
+ calcd for
C22H28FN4O5 447.20382, found 447.20355.
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.7b00470




Donor 3 and acceptor 26 were condensed using the general procedure
for Tf2O/Ph2SO-mediated glycosylations (for an additional 18 h at
−40 °C) and purified by flash column chromatography (19:1 to 4:1
pentane/EtOAc) to yield glycosylation product 3E (73.3 mg, 88 μmol,
88%, α/β = 1:7) as a white solid. Rf 0.51 α, 0.43 β (4:1 pentane/
EtOAc). IR (neat): 696, 737, 1049, 1092, 1362, 1454, 2110, 2868.
Data for the β-anomer: 1H NMR (CDCl3, 400 MHz, H−H COSY,
HSQC, TOCSY): δ 7.68−7.60 (m, 2H, CHarom), 7.52−7.18 (m, 23H,
CHarom), 5.47 (s, 1H, CHPh), 4.89 (d, 1H, J = 11.2 Hz, CHH Bn),
4.87 (d, 1H, J = 10.9 Hz, CHH Bn), 4.81 (d, 1H, J = 10.9 Hz, CHH
Bn), 4.78 (d, 1H, J = 12.2 Hz, CHH Bn), 4.75 (d, 1H, J = 11.2 Hz,
CHH Bn), 4.71 (d, 1H, J = 12.0 Hz, CHH Bn), 4.63 (d, 1H, J = 12.1
Hz, CHH Bn), 4.60 (d, 1H, J = 3.7 Hz, H-1), 4.41 (d, 1H, J = 12.0 Hz,
CHH Bn), 4.19 (d, 1H, J = 7.6 Hz, H-1′), 4.11 (dd, 1H, J = 10.6, 5.0
Hz, H-6′), 4.00−3.90 (m, 2H, H-4, H-6), 3.85 (t, 1H, J = 9.3 Hz, H-3),
3.75 (dt, 1H, J = 9.8, 2.4 Hz, H-5), 3.69 (dd, 1H, J = 10.8, 1.9 Hz, H-
6), 3.56 (t, 1H, J = 9.0 Hz, H-4′), 3.51 (dd, 1H, J = 9.5, 3.7 Hz, H-2),
3.45−3.38 (m, 4H, H-6′, CH3 OMe), 3.36−3.27 (m, 2H, H-2′, H-3′),
3.00 (td, 1H, J = 9.8, 5.0 Hz, H-5′). 13C-APT NMR (CDCl3, 101
MHz, HSQC): δ 139.3, 138.3, 137.8, 137.8, 137.3 (Cq), 131.1, 129.4,
128.6, 128.4, 128.3, 128.2, 128.2, 128.1, 128.1, 127.9, 127.9, 127.6,
126.0, 124.8 (CHarom), 101.3, 101.2 (CHPh, C-1′), 98.4 (C-1), 81.7
(C-4′), 80.1 (C-3), 79.2 (C-3′), 79.0 (C-2), 76.9 (C-4), 75.4, 74.7,
73.6, 73.5 (CH2 Bn), 69.7 (C-5), 68.6 (C-6′), 68.0 (C-6), 66.6 (C-2′),
65.8 (C-5′), 55.4 (OMe). Diagnostic peaks for the α-anomer: 1H
NMR (CDCl3, 400 MHz): δ 5.71 (d, 1H, J = 4.0 Hz, H-1′), 5.53 (s,
1H, CHPh), 5.11 (d, 1H, J = 10.7 Hz, CHH Bn), 4.95 (d, 1H, J = 10.9
Hz, CHH Bn). 13C-APT NMR (CDCl3, 101 MHz): δ 98.1, 97.8, 82.7,
82.1, 80.5, 76.2, 75.1, 73.3, 73.0, 69.4, 69.1, 68.7, 63.4, 62.9. HRMS:
[M + Na]+ calcd for C48H51N3O10Na 852.34667, found 852.34668.
Methyl (Methyl 4-O-[2-Azido-3-O-benzyl-4,6-O-benzylidene-2-
deoxy-α/β-D-glucopyranosyl]-2,3-di-O-benzyl-α-D-glucopyranosyl
uronate) (3F). Donor 3 and acceptor 27 were condensed using the
general procedure for Tf2O/Ph2SO-mediated glycosylations (for an
additional 18 h at −40 °C) and purified by flash column
chromatography (19:1 to 4:1 pentane/EtOAc) to yield glycosylation
product 3F (71.8 mg, 93 μmol, 93%, α/β = 1.1:1) as a white solid. Rf
0.54 (4:1 pentane/EtOAc). Spectroscopic data were in accord with
those reported previously.21 IR (neat): 696, 735, 914, 989, 1028, 1045,
1090, 1267, 1369, 1454, 1749, 2108, 2870, 2916. Data reported for a
1:1 mixture of anomers: 1H NMR (CDCl3, 400 MHz, H−H COSY,
HSQC, HMBC): δ 7.48−7.41 (m, 4H, CHarom), 7.41−7.24 (m, 36H,
CHarom), 5.53 (s, 1H, CHPhα), 5.51 (d, 1H, J = 3.9 Hz, H-1′α), 5.47 (s,
1H, CHPhβ), 5.04 (d, 1H, J = 10.5 Hz, CHH Bn), 4.94 (d, 1H, J =
11.0 Hz, CHH Bn), 4.91−4.82 (m, 4H, 2 × CHH Bn, 2 × CHH Bn),
4.81−4.72 (m, 4H, 2 × CHH Bn, 2 × CHH Bn), 4.64−4.58 (m, 2H, 2
× CHH Bn), 4.57 (d, 2H, J = 3.5 Hz, H-1α,β), 4.43 (d, 1H, J = 8.1 Hz,
H-1′β), 4.26 (dd, 1H, J = 10.3, 4.8 Hz, H-6′α), 4.24−4.19 (m, 2H, H-
5α, H-5β), 4.09−3.99 (m, 4H, H-3β, H-4α, H-4β, H-6′β), 3.97 (t, 1H, J =
9.5 Hz, H-3′α), 3.89 (t, 1H, J = 9.2 Hz, H-3α), 3.82 (s, 3H, CH3
CO2Me), 3.81 (s, 3H, CH3 CO2Me), 3.72−3.56 (m, 4H, H-2β, H-4′α,
H-4′β, H-6′α), 3.56−3.46 (m, 3H, H-2α, H-3′β, H-5′α), 3.46−3.38 (m,
7H, 2 × CH3 OMe, H-6′β), 3.36−3.29 (m, 2H, H-2′α, H-2′β), 3.26 (td,
1H, J = 9.7, 5.0 Hz, H-5′β). 13C-APT NMR (CDCl3, 101 MHz,
HSQC, HMBC): δ 170.0, 170.0 (CO CO2Me), 139.1, 138.5, 138.0,
137.9, 137.9, 137.8, 137.4, 137.2 (Cq), 129.2, 129.1, 128.7, 128.6,
128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.3, 128.2, 128.1, 128.0,
128.0, 127.8, 127.7, 127.5, 127.4, 126.1, 126.1 (CHarom), 102.3 (C-1′β),
101.4 (CHPhβ), 101.3 (CHPhα), 98.9, 98.6 (C-1α, C-1β), 98.5 (C-1′
α), 82.4 (C-4′α), 81.6 (C-4′β), 81.1 (C-3β), 79.6 (C-2β, C-4β), 79.5 (C-
3α), 79.4 (C-3′β), 78.7 (C-2α), 76.3 (C-3′α), 75.6 (CH2 Bn), 75.5 (C-
4α), 75.1, 75.0, 73.9, 73.7 (CH2 Bn), 70.0, 69.9 (C-5α, C-5β), 68.5, 68.5
(C-6α, C-6β), 66.7 (C-2′β), 66.2 (C-5′β), 63.0 (C-5′α), 62.8 (C-2′α),
55.9, 55.9 (OMe), 53.0, 52.8 (CO2Me). HRMS: [M + NH4]
+ calcd for
C42H49N4O11 785.33923, found 785.34007.
2,2-Difluoroethyl 2-Azido-3-O-benzyl-4,6-O-benzylidene-2-
deoxy-α/β-D-glucopyranoside (3G). Donor 3 and 2,2-difluoroethanol
were condensed using the general procedure for Tf2O/Ph2SO-
mediated glycosylations and purified by flash column chromatography
(1:0 to 0:1 pentane/toluene to 5% EtOAc in toluene) to yield
glycosylation product 3G (28.8 mg, 64 μmol, 64%, α/β = 2.9:1) as a
white solid. Rf 0.15 and 0.18 (toluene). IR (neat): 698, 747, 998, 1070,
1093, 1372, 1454, 2109, 2867, 2934. Data reported for a 1:0.35
mixture of anomers: 1H NMR (CDCl3, 400 MHz, H−H COSY,
HSQC): δ 7.52−7.45 (m, 2.70H, CHarom), 7.43−7.26 (m, 10.80H,
CHarom), 5.95 (tt, 1H, J = 55.2, 4.2 Hz, CF2Hα), 5.94 (tt, 0.35H, J =
55.3, 3.8 Hz, CF2Hβ), 5.58 (s, 1H, CHPhα), 5.57 (s, 0.35H, CHPhβ),
4.96 (d, 1H, J = 10.9 Hz, CHH Bnα), 4.93 (d, 1H, J = 3.9 Hz, H-1α),
4.92 (d, 0.35H, J = 11.3 Hz, CHH Bnβ), 4.80 (d, 1H, J = 11.0 Hz,
CHH Bnα), 4.79 (d, 0.35H, J = 11.3 Hz, CHH Bnβ), 4.40 (d, 0.35H, J
= 7.9 Hz, H-1β), 4.34 (dd, 0.35H, J = 10.5, 5.0 Hz, H-6β), 4.29 (dd,
1H, J = 10.2, 4.8 Hz, H-6α), 4.08 (t, 1H, J = 9.5 Hz, H-3α), 4.02−3.67
(m, 6.4H, H-4α, H-4β, H-5α, H-6α, H-6β, CH2CF2Hα, CH2
CF2Hβ), 3.56 (t, 0.35H, J = 9.2 Hz, H-3β), 3.50−3.35 (m, 1.70H, H-2α,
H-2β, H-5β).
13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.8,
137.8, 137.1, 137.1 (Cq), 129.4, 129.3, 129.1, 128.6, 128.5, 128.5,
128.4, 128.1, 126.1 (CHarom), 114.0 (t, J = 241.5 Hz, CF2Hβ), 113.8 (t,
J = 241.6 Hz, CF2Hα), 102.8 (C-1β), 101.6 (CHPhα), 101.5 (CHPhβ),
99.3 (C-1α), 82.6 (C-4α), 81.4 (C-4β), 78.9 (C-3β), 76.0 (C-3α), 75.3
(CH2 Bnα), 75.1 (CH2 Bn), 69.0 (t, J = 29.0 Hz, CH2CF2Hβ), 68.8
(C-6), 68.5 (C-6), 67.5 (t, J = 28.7 Hz, CH2CF2Hα), 66.4 (C-5β),
66.0 (C-2β), 63.3 (C-5α), 62.9 (C-2α). HRMS: [M + H]
+ calcd for
C22H24F2N3O5 448.16785, found 448.16761.
Methyl 4-O-(2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-
D-glucopyranosyl)-2,3,6-tri-O-benzyl-β-D-galactopyranoside (3H).
Donor 3 and acceptor 28 were condensed using the general procedure
for Tf2O/Ph2SO-mediated glycosylations (for an additional 18 h at
−40 °C) and purified by flash column chromatography (19:1 to 4:1
pentane/EtOAc) to yield glycosylation product 3H (62.2 mg, 75
μmol, 75%, α/β = 9:1) as a white solid. Rf 0.52 (4:1 pentane/EtOAc).
IR (neat): 696, 735, 995, 1030, 1072, 1090, 1368, 1454, 1497, 2106,
2862, 2920. Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, H−
H COSY, HSQC, HMBC): δ 7.50−7.46 (m, 2H, CHarom), 7.42−7.25
(m, 23H, CHarom), 5.51 (s, 1H, CHPh), 4.98 (d, 1H, J = 10.7 Hz,
CHH 3′-OBn), 4.90 (d, 1H, J = 11.0 Hz, CHH 2-OBn), 4.88 (d, 1H, J
= 3.7 Hz, H-1′), 4.84−4.76 (m, 3H, CHH 2-OBn, CHH 3′-OBn,
CHH 3-OBn), 4.69 (d, 1H, J = 12.4 Hz, CHH 3-OBn), 4.59−4.51 (m,
2H, CH2 6-OBn), 4.30 (td, 1H, J = 10.1, 4.9 Hz, H-5′), 4.25 (d, 1H, J
= 7.6 Hz, H-1), 4.14−4.07 (m, 2H, H-3′, H-4), 4.03 (t, 1H, J = 8.9 Hz,
H-6), 3.80 (dd, 1H, J = 10.2, 4.9 Hz, H-6′), 3.70−3.60 (m, 3H, H-2,
H-4′, H-6), 3.55 (s, 3H, CH3 OMe), 3.54−3.48 (m, 2H, H-5, H-6′),
3.44−3.36 (m, 2H, H-2′, H-3). 13C-APT NMR (CDCl3, 101 MHz,
HSQC, HMBC): δ 138.7, 138.3, 138.1, 137.7, 137.6 (Cq), 129.0,
128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.2, 128.0, 127.7,
127.6, 126.1 (CHarom), 105.3 (C-1), 101.2 (CHPh), 99.4 (C-1′), 83.1
(C-4′), 80.1 (C-3), 78.9 (C-2), 77.0 (C-3′), 75.3 (CH2 3′-OBn), 75.1
(CH2 2-OBn), 74.7 (C-4), 73.6 (CH2 6-OBn), 73.0 (CH2 3-OBn),
72.9 (C-5), 68.9 (C-6′), 67.1 (C-6), 63.8 (C-2′), 62.9 (C-5′), 57.4
(OMe). Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 400
MHz): δ 5.54 (s, 1H, CHPh), 3.92 (dd, 1H, J = 9.7, 7.7 Hz, H-2),
3.76−3.71 (m, 1H, H-6), 3.22 (td, 1H, J = 9.7, 4.8 Hz, H-5′). 13C-APT
NMR (CDCl3, 101 MHz): δ 105.1 (C-1), 102.6 (C-1′), 101.4, 81.5,
81.3, 79.5, 79.0, 74.0, 73.4, 69.4, 68.6, 66.3, 66.0, 57.4. HRMS: [M +
NH4]
+ calcd for C48H55N4O10 847.39127, found 847.39206.
Methyl 2-O-(2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-
D-glucopyranosyl)-3-O-benzyl-4,6-O-benzylidene-α-D-mannopyra-
noside (3I). Donor 3 and acceptor 29 were condensed using the
general procedure for Tf2O/Ph2SO-mediated glycosylations (for an
additional 18 h at −40 °C) and purified by flash column
chromatography (19:1 to 4:1 pentane/EtOAc) to yield glycosylation
product 3I (54.7 mg, 74 μmol, 74%, α/β = 9:1) as a white solid. Rf
0.74 (7/2 pentane/EtOAc). IR (neat): 696, 746, 997, 1036, 1074,
1090, 1128, 1371, 1454, 2106, 2862, 2922. Data for the α-anomer: 1H
NMR (CDCl3, 400 MHz, H−H COSY, HSQC, HMBC): δ 7.54−7.47
(m, 4H, CHarom), 7.44−7.25 (m, 16H, CHarom), 5.66 (s, 1H, CHPh),
5.60 (s, 1H, CHPh′), 5.39 (d, 1H, J = 3.7 Hz, H-1′), 5.00 (d, 1H, J =
11.0 Hz, CHH Bn), 4.90 (d, 1H, J = 12.2 Hz, CHH Bn), 4.84 (d, 1H, J
= 10.9 Hz, CHH Bn), 4.73−4.66 (m, 2H, H-1, CHH Bn), 4.34−4.24
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(m, 3H, H-4, H-6, H-6′), 4.17 (dd, 1H, J = 10.2, 9.0 Hz, H-3′), 4.09
(dd, 1H, J = 3.1, 1.7 Hz, H-2), 4.00 (dd, 1H, J = 9.9, 3.1 Hz, H-3),
3.95−3.86 (m, 2H, H-5′, H-6), 3.83−3.70 (m, 3H, H-4′, H-5, H-6′),
3.36 (s, 3H, CH3 OMe), 3.32 (dd, 1H, J = 10.2, 3.8 Hz, H-2′). 13C-
APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 138.7, 138.0, 137.7,
137.2 (Cq), 129.2, 129.0, 128.6, 128.5, 128.4, 128.3, 128.2, 128.0,
127.6, 127.4, 126.2, 126.0 (CHarom), 101.7 (CHPh), 101.5 (CHPh′),
101.0 (C-1), 99.8 (C-1′), 82.9 (C-4′), 79.4 (C-4), 75.9 (C-3), 75.6 (C-
3′), 75.5 (C-2), 75.3, 73.3 (CH2 Bn), 69.0, 68.9 (C-6, C-6′), 64.1 (C-
5), 63.3 (C-5′), 63.0 (C-2′), 55.0 (OMe). Diagnostic peaks for the β-
anomer: 1H NMR (CDCl3, 400 MHz): δ 4.43 (d, 0.1H, J = 8.0 Hz, H-
1′), 3.62 (dd, 0.1H, J = 9.6, 8.0 Hz, H-2′), 3.51 (t, 0.1H, J = 9.3 Hz, H-
4). 13C-APT NMR (CDCl3, 101 MHz): δ 102.0 (C-1′), 78.5 (C-4),
66.4 (C-2′). HRMS: [M + NH4]+ calcd for C41H47N4O10 755.32867,
found 755.32921.
2,2,2-Trifluoroethyl 2-Azido-3-O-benzyl-4,6-O-benzylidene-2-
deoxy-α-D-glucopyranoside (3J). Donor 3 and 2,2,2-trifluoroethanol
were condensed using the general procedure for Tf2O/Ph2SO-
mediated glycosylations (for an additional 1 h at −40 °C) and
purified by flash column chromatography (1:0 to 0:1 pentane/toluene
to 5% EtOAc in toluene) to yield glycosylation product 3J (44 mg, 94
μmol, 94%, α/β > 20:1) as a colorless oil. Rf 0.24 (toluene). [α]D
23 =
+25.9° (c = 0.88, DCM). IR (neat): 697, 747, 1001, 1034, 1090, 1165,
1279, 1373, 2108, 2865, 2934. Data for the α-anomer: 1H NMR
(CDCl3, 400 MHz, H−H COSY, HSQC): δ 7.51−7.48 (m, 2H,
CHarom), 7.42−7.28 (m, 8H, CHarom), 5.58 (s, 1H, CHPh), 4.99−4.94
(m, 2H, CHH Bn, H-1), 4.80 (d, 1H, J = 10.9 Hz, CHH Bn), 4.29 (dd,
1H, J = 10.2, 4.8 Hz, H-6), 4.10 (dd, 1H, J = 10.0, 9.0 Hz, H-3), 3.98
(qd, 2H, J = 8.5, 3.1 Hz, CH2CF3), 3.91 (td, 1H, J = 9.9, 4.8 Hz, H-
5), 3.79−3.70 (m, 2H, H-4, H-6), 3.43 (dd, 1H, J = 10.0, 3.7 Hz, H-2).
13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 137.8, 137.1 (Cq),
129.3, 128.6, 128.5, 128.3, 128.1, 126.1 (CHarom), 123.5 (q, J = 278.5
Hz), 101.6 (CHPh), 99.4 (C-1), 82.5 (C-4), 75.9 (C-3), 75.3 (CH2
Bn), 68.7 (C-6), 65.4 (q, J = 35.4 Hz), 63.5 (C-5), 62.7 (C-2). 13C-
HMBC-GATED NMR (CDCl3, 101 MHz): δ 102.5 (JC1,H1 = 173 Hz,
C-1). Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 400
MHz): δ 4.44 (d, 0.03H, J = 7.9 Hz, H-1), 4.34 (dd, 0.03H, J = 10.8,
5.3 Hz, H-6), 3.56 (t, 0.03H, J = 9.2 Hz), 3.48 (dd, 0.03H, J = 10.0, 7.9
Hz, H-2). 13C-HMBC-GATED NMR (CDCl3, 101 MHz): δ 102.4
(JC−H = 150 Hz, C-1). HRMS: [M + NH4]
+ calcd for C22H26F3N4O5
483.18498, found 483.18463.
1,1,1,3,3,3-Hexafluoro-2-propyl 2-Azido-3-O-benzyl-4,6-O-benzy-
lidene-2-deoxy-α-D-glucopyranoside (3K). Donor 3 and 1,1,1,3,3,3-
hexafluoroisopropanol were condensed using the general procedure
for Tf2O/Ph2SO-mediated glycosylations (for an additional 72 h at
−40 °C) and purified by flash column chromatography (1:0 to 9:1
pentane/EtOAc) to yield glycosylation product 3K (28.1 mg, 53 μmol,
53%, α/β > 20:1) as a colorless oil. [α]D
23 = +25.8° (c = 0.5, CHCl3).
IR (neat): 689, 748, 999, 1092, 1196, 1219, 1287, 1368, 2108, 2868,
2928. 1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC): δ 7.54−
7.45 (m, 2H, CHarom), 7.44−7.27 (m, 8H, CHarom), 5.59 (s, 1H,
CHPh), 5.13 (d, 1H, J = 3.9 Hz, H-1), 4.99 (d, 1H, J = 10.8 Hz, CHH
Bn), 4.82 (d, 1H, J = 10.8 Hz, CHH Bn), 4.40 (hept, 1H, J = 5.9 Hz,
CH HFIP), 4.26 (dd, 1H, J = 10.3, 4.9 Hz, H-6), 4.10 (dd, 1H, J =
10.0, 9.1 Hz, H-3), 3.98 (td, 1H, J = 10.0, 4.9 Hz, H-5), 3.80−3.73 (m,
2H, H-4, H-6), 3.51 (dd, 1H, J = 10.1, 3.9 Hz, H-2). 13C-APT NMR
(CDCl3, 101 MHz, HSQC): δ 137.6, 136.9 (Cq), 129.3, 128.6, 128.5,
128.4, 128.2, 126.1 (CHarom), 120.9 (q, J = 283 Hz, CF3), 101.6
(CHPh), 101.0 (C-1), 82.1 (C-4), 75.9 (C-3), 75.5 (CH2 Bn), 74.0,
73.7 (hept, J = 32.8 Hz, CH HFIP), 68.3 (C-6), 64.2 (C-5), 62.5 (C-
2). HRMS: [M + H]+ calcd for C23H21F6N3O5 534.14582, found
534.14569.
Ethyl 2-Azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-β-D-glu-
copyranoside (4A). Donor 4 and ethanol were condensed using the
general procedure for Tf2O/Ph2SO-mediated glycosylations and
purified by flash column chromatography (1:1:0 to 0:1:0 to 0:19:1
pentane/toluene/EtOAc) to yield glycosylation product 4A (36 mg,
85 μmol, 85%, α/β < 1:20) as a white solid. Rf 0.44 (19:1 toluene/
EtOAc). [α]D
23 = −53.7° (c = 1.04, DCM). IR (thin film): 709, 1001,
1026, 1070, 1094, 1180, 1263, 1375, 1726, 2110, 2872. Data for the β-
anomer: 1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC): δ 8.11−
8.05 (m, 2H, CHarom), 7.60−7.55 (m, 1H, CHarom), 7.48−7.43 (m, 2H,
CHarom), 7.40−7.35 (m, 2H, CHarom), 7.32−7.27 (m, 3H, CHarom),
5.50 (s, 1H, CHPh), 5.40 (t, 1H, J = 9.8 Hz, H-3), 4.59 (d, 1H, J = 7.9
Hz, H-1), 4.38 (dd, 1H, J = 10.6, 5.0 Hz, H-6), 4.02 (dq, 1H, J = 9.5,
7.1 Hz, CHH Et), 3.83 (t, 1H, J = 10.3 Hz, H-6), 3.80−3.67 (m, 2H,
H-4, CHH Et), 3.64 (dd, 1H, J = 10.0, 7.9 Hz, H-2), 3.56 (td, 1H, J =
9.7, 5.0 Hz, H-5), 1.32 (t, 3H, J = 7.1 Hz, CH3 Et).
13C-APT NMR
(CDCl3, 101 MHz, HSQC): δ 165.5 (CO Bz), 136.9 (Cq), 133.4,
130.1 (CHarom), 129.7 (Cq), 129.2, 128.6, 128.3, 126.2 (CHarom), 102.8
(C-1), 101.6 (CHPh), 79.0 (C-4), 71.8 (C-3), 68.7 (C-6), 66.6, 66.6
(C-5, CH2 Et), 65.0 (C-2), 15.2 (CH3 Et). Diagnostic peaks for the α-
anomer: 1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC): δ 5.88
(t, 0.03H, J = 9.9 Hz, H-3), 5.53 (s, 0.03H, CHPh), 5.06 (d, 0.03H, J =
3.6 Hz, H-1), 4.32 (dd, 0.03H, J = 10.4, 4.9 Hz, H-6), 3.32 (dd, 0.03H,
J = 10.3, 3.6 Hz, H-2). HRMS: [M + NH4]
+ calcd for C22H27N4O6
443.19251, found 443.19234.
Cyclohexyl 2-Azido-3-O-benozyl-4,6-O-benzylidene-2-deoxy-β-D-
glucopyranoside (4B). Donor 4 and cyclohexanol were condensed
using the general procedure for Tf2O/Ph2SO-mediated glycosylations
and purified by flash column chromatography (1:1:0 to 0:1:0 to 0:19:1
pentane/toluene/EtOAc) to yield glycosylation product 4B (43.6 mg,
91 μmol, 91%, α/β < 1:20) as a white solid. Rf 0.18 (toluene). [α]D
23 =
−41.2° (c = 0.87, DCM). IR (thin film): 613, 708, 999, 1096, 1263,
1730, 2110, 2859, 2934. 1H NMR (CDCl3, 400 MHz, H−H COSY,
HSQC): δ 8.11−8.05 (m, 2H, CHarom), 7.61−7.54 (m, 1H, CHarom),
7.49−7.42 (m, 2H, CHarom), 7.41−7.35 (m, 2H, CHarom), 7.31−7.27
(m, 3H, CHarom), 5.50 (s, 1H, CHPh), 5.38 (t, 1H, J = 9.9 Hz, H-3),
4.70 (d, 1H, J = 7.9 Hz, H-1), 4.37 (dd, 1H, J = 10.6, 5.0 Hz, H-6),
3.89−3.71 (m, 3H, H-4, H-6, CHO Cyc), 3.64 (dd, 1H, J = 10.1, 7.9
Hz, H-2), 3.55 (td, 1H, J = 9.8, 5.0 Hz, H-5), 2.04−1.90 (m, 2H, 2 ×
CHH Cyc), 1.85−1.73 (m, 2H, 2 × CHH Cyc), 1.58−1.40 (m, 3H,
CHH Cyc, 2 × CHH Cyc), 1.39−1.20 (m, 3H, 3 × CHH Cyc). 13C-
APT NMR (CDCl3, 101 MHz, HSQC): δ 165.5 (C = O Bz), 136.9
(Cq), 133.4, 130.0 (CHarom), 129.7 (Cq), 129.2, 128.5, 128.3, 126.2
(CHarom), 101.6 (CHPh), 101.2 (C-1), 79.0 (C-4), 78.8 (CH Cyc),
71.8 (C-3), 68.7 (C-6), 66.6 (C-5), 65.2 (C-2), 33.7, 31.7, 25.6, 24.1,
23.9 (CH2 Cyc). HRMS: [M + NH4]




Donor 4 and acceptor 25 were condensed using the general procedure
for Tf2O/Ph2SO-mediated glycosylations (for an additional 18 h at
−40 °C) and purified by flash column chromatography (19:1 to 3/1
pentane/EtOAc) to yield glycosylation product 4C (67 mg, 79 μmol,
79%, α/β = 1:14) as a white solid. Rf 0.24 (4:1 pentane/EtOAc). [α]D
20
= −17.5° (c = 1.34, CHCl3). IR (thin film): 696, 748, 1002, 1028,
1068, 1092, 1263, 1313, 1369, 1452, 1730, 2110, 2872, 2918. Data for
the β-anomer: 1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC,
HMBC): δ 8.09−8.04 (m, 2H, CHarom), 7.60−7.53 (m, 1H, CHarom),
7.48−7.41 (m, 2H, CHarom), 7.40−7.24 (m, 20H, CHarom), 5.47 (s, 1H,
CHPh), 5.42 (t, 1H, J = 9.8 Hz, H-3′), 5.00 (d, 1H, J = 10.9 Hz, CHH
Bn), 4.95 (d, 1H, J = 11.1 Hz, CHH Bn), 4.84 (d, 1H, J = 11.0 Hz,
CHH Bn), 4.80 (d, 1H, J = 12.2 Hz, CHH Bn), 4.68−4.63 (m, 2H, 2
× CHH Bn), 4.61 (d, 1H, J = 3.5 Hz, H-1), 4.43 (d, 1H, J = 8.0 Hz, H-
1′), 4.33 (dd, 1H, J = 10.5, 5.0 Hz, H-6′), 4.12 (d, 1H, J = 9.1 Hz, H-
6), 4.02 (t, 1H, J = 9.3 Hz, H-3), 3.84−3.72 (m, 4H, H-4′, H-5, H-6,
H-6′), 3.69 (dd, 1H, J = 9.9, 8.0 Hz, H-2′), 3.57 (t, 1H, J = 9.2 Hz, H-
4), 3.54 (dd, 1H, J = 9.7, 3.6 Hz, H-2), 3.49 (td, 1H, J = 9.8, 5.0 Hz, H-
5′), 3.39 (s, 3H, CH3 OMe). 13C-APT NMR (CDCl3, 101 MHz,
HSQC, HMBC): δ 165.4 (CO), 138.7, 138.3, 138.2, 136.7
(CHarom), 133.5, 130.0 (CHarom), 129.4 (Cq Bz), 129.1, 128.6, 128.6,
128.5, 128.5, 128.3, 128.3, 128.1, 128.0, 128.0, 127.9, 127.9, 127.7,
126.1 (CHarom), 102.6 (C-1′), 101.5 (CHPh), 98.3 (C-1), 82.1 (C-3),
79.8 (C-2), 78.7 (C-4′), 77.7 (C-4), 75.8, 75.0, 73.6 (CH2 Bn), 71.9
(C-3′), 69.7 (C-5), 68.9 (C-6), 68.5 (C-6′), 66.6 (C-5′), 65.2 (C-2′),
55.4 (CH3 OMe). Diagnostic peaks for the α-anomer:
1H NMR
(CDCl3, 400 MHz): δ 5.79 (t, 0.07H, J = 9.9 Hz, H-3′), 5.50 (s,
0.07H, CHPh), 5.08 (d, 0.07H, J = 3.5 Hz, H-1′), 4.24 (dd, 0.07H, J =
10.3, 4.8 Hz, H-6′), 3.41 (s, 0.21H, CH3 OMe). 13C-APT NMR
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(CDCl3, 101 MHz): δ 101.7 (CHPh), 99.3 (C-1′), 98.1 (C-1), 82.1,
80.0, 79.7, 77.6, 75.8, 75.2, 70.0, 69.4, 67.0, 62.8, 62.1, 55.4. HRMS:
[M + NH4]
+ calcd for C48H53N4O11 861.37053, found 861.37064.
2-Fluoroethyl 2-Azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-
α/β-D-glucopyranoside (4D). Donor 4 and 2-fluoroethanol were
condensed using the general procedure for Tf2O/Ph2SO-mediated
glycosylations and purified by flash column chromatography (1:1:0 to
0:1:0 to 0:16:1 pentane/toluene/EtOAc) to yield glycosylation
product 4D (36.6 mg, 83 μmol, 83%, α/β = 1:6.5) as a white solid.
Rf 0.41 (19:1 toluene/EtOAc). IR (thin film): 700, 748, 879, 1001,
1026, 1070, 1093, 1179, 1261, 1722, 2108, 2868. Data for the β-
anomer: 1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC): δ 8.10−
8.05 (m, 2H, CHarom), 7.61−7.54 (m, 1H, CHarom), 7.49−7.43 (m, 2H,
CHarom), 7.41−7.36 (m, 2H, CHarom), 7.33−7.27 (m, 3H, CHarom),
5.50 (s, 1H, CHPh), 5.41 (t, 1H, J = 9.8 Hz, H-3), 4.69 (ddt, 1H, J =
4.6, 3.2, 1.8 Hz, CHHCH2F), 4.65 (d, 1H, J = 7.9 Hz, H-1), 4.58
(ddt, 1H, J = 4.5, 3.3, 1.8 Hz, CHHCH2F), 4.38 (dd, 1H, J = 10.5,
4.9 Hz, H-6), 4.14 (dddd, 1H, J = 30.3, 11.9, 4.6, 3.1 Hz, CHHF), 3.95
(dddd, 1H, J = 27.1, 12.1, 5.5, 3.4 Hz, CHHF), 3.83 (t, 1H, J = 10.3
Hz, H-6), 3.79 (t, 1H, J = 9.5 Hz, H-4), 3.69 (dd, 1H, J = 10.0, 7.9 Hz,
H-2), 3.57 (td, 1H, J = 9.7, 5.0 Hz, H-5). 13C-APT NMR (CDCl3, 101
MHz, HSQC): δ 165.4 (CO), 136.8 (Cq Ph), 133.5, 130.0
(CHarom), 129.5 (Cq Bz), 129.2, 128.6, 128.5, 128.3, 126.3, 126.2
(CHarom), 103.0 (C-1), 101.6 (CHPh), 82.5 (d, J = 170.5 Hz, CH2F),
78.8 (C-4), 71.7 (C-3), 69.5 (d, J = 20.2 Hz, CH2CH2F), 68.5 (C-
6), 66.7 (C-5), 64.9 (C-2). Diagnostic peaks for the α-anomer: 1H
NMR (CDCl3, 400 MHz): δ 5.89 (t, 0.17H, J = 9.9 Hz, H-3), 5.53 (s,
0.17H, CHPh), 5.12 (d, 0.17H, J = 3.6 Hz, H-1), 4.33 (dd, 0.17H, J =
10.4, 5.0 Hz, H-6), 3.38 (dd, 0.17H, J = 10.4, 3.6 Hz, H-2). 13C-APT
NMR (CDCl3, 101 MHz): δ 101.8, 99.5 (C-1), 82.4 (d, J = 170.8 Hz),
79.6, 68.9, 67.8 (d, J = 20.2 Hz), 63.1, 61.8. HRMS: [M + NH4]
+ calcd
for C22H26FN4O6 461.18309, found 461.18292.
Methyl 4-O-(2-Azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α/
β-D-glucopyranosyl)-2,3,6-tri-O-benzyl-α-D-glucopyranoside (4E).
Donor 4 and acceptor 26 were condensed using the general procedure
for Tf2O/Ph2SO-mediated glycosylations (for an additional 18 h at
−40 °C) and purified by flash column chromatography (19:1 to 4:1
pentane/EtOAc) to yield glycosylation product 4E (60 mg, 71 μmol,
71%, α/β = 1:6) as a white solid. Rf 0.67 (4:1 pentane/EtOAc). IR
(thin film): 696, 733, 914, 999, 1026, 1045, 1090, 1177, 1263, 1314,
1366, 1452, 1730, 2108, 2866, 2899. Data for the β-anomer: 1H NMR
(CDCl3, 400 MHz, H−H COSY, HSQC, HMBC): δ 8.10−8.04 (m,
2H, CHarom), 7.61−7.53 (m, 1H, CHarom), 7.49−7.24 (m, 22H,
CHarom), 5.40 (s, 1H, CHPh), 5.19 (t, 1H, J = 9.8 Hz, H-3′), 4.90 (d,
1H, J = 10.8 Hz, CHH Bn), 4.83 (d, 1H, J = 10.8 Hz, CHH Bn), 4.81−
4.73 (m, 2H, 2 × CHH Bn), 4.67−4.60 (m, 2H, CHH Bn, H-1), 4.42
(d, 1H, J = 12.0 Hz, CHH Bn), 4.31 (d, 1H, J = 8.0 Hz, H-1′), 4.17
(dd, 1H, J = 10.6, 5.0 Hz, H-6′), 4.08−3.98 (t, 1H, J = 9.4 Hz, H-4),
3.96 (dd, 1H, J = 10.8, 2.4 Hz, H-6), 3.86 (t, 1H, J = 9.3 Hz, H-3),
3.79−3.74 (m, 1H, H-5), 3.71 (dd, 1H, J = 10.7, 1.7 Hz, H-6), 3.61 (t,
1H, J = 9.5 Hz, H-4′), 3.54 (dd, 1H, J = 9.6, 3.7 Hz, H-2), 3.52−3.45
(m, 2H, H-2′, H-6′), 3.39 (s, 3H, CH3 OMe), 3.08 (td, 1H, J = 9.7, 5.0
Hz, H-5′). 13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ
165.3 (CO), 139.3, 138.3, 137.6, 136.9 (Cq), 133.4, 129.9 (CHarom),
128.9 (Cq Bz), 128.6, 128.5, 128.5, 128.3, 128.3, 128.2, 127.9, 127.8,
126.2 (CHarom), 101.5, 101.4 (CHPh, C-1′), 98.4 (C-1), 80.1 (C-3),
79.1 (C-2), 78.9 (C-4′), 76.8 (C-4), 75.6, 73.7, 73.6 (CH2 Bn), 72.0
(C-3′), 69.7 (C-5), 68.6 (C-6′), 67.8 (C-6), 66.1 (C-5′), 65.6 (C-2′),
55.5 (OMe). Diagnostic peaks for the α-anomer: 1H NMR (CDCl3,
400 MHz): δ 5.91 (d, 0.17H, J = 3.9 Hz, H-1′), 5.80 (t, 0.17H, J = 10.0
Hz, H-3′), 5.47 (s, 0.17H, CHPh), 5.15 (d, 0.17H, J = 10.7 Hz, CHH
Bn), 4.74 (d, 0.17H, J = 12.0 Hz, CHH Bn), 4.09 (t, 0.17H, J = 9.2
Hz), 3.29 (dd, 0.17H, J = 10.5, 3.9 Hz, H-2′). 13C-APT NMR (CDCl3,
101 MHz): δ 165.6, 138.6, 138.1, 137.9, 137.0, 133.4, 130.0, 129.6,
129.0, 128.6, 128.6, 128.5, 128.4, 128.2, 128.1, 127.6, 127.6, 127.4,
101.6 (CHPh), 98.6 (C-1′), 97.7 (C-1), 82.1, 80.7, 79.5, 75.0, 73.6,
73.3, 72.8, 69.5, 69.3, 68.9, 68.7, 63.7, 61.9, 55.5. HRMS: [M + NH4]
+
calcd for C48H53N4O11 861.37053, found 861.37081.
Methyl (Methyl 4-O-[2-Azido-3-O-benzoyl-4,6-O-benzylidene-2-
deoxy-α/β-D-glucopyranosyl]-2,3-di-O-benzyl-α-D-glucopyranosyl
uronate) (4F). Donor 4 and acceptor 27 were condensed using the
general procedure for Tf2O/Ph2SO-mediated glycosylations (for an
additional 18 h at −40 °C) and purified by flash column
chromatography (19:1 to 4:1 pentane/EtOAc) to yield glycosylation
product 4F (46 mg, 59 μmol, 59%, α/β = 1:1.4) as a white solid. Rf
0.56 (4:1 pentane/EtOAc). IR (thin film): 698, 750, 991, 1026, 1047,
1092, 1178, 1263, 1452, 1730, 2110, 2868, 2938. Data reported for a
0.7:1 mixture of anomers: 1H NMR (CDCl3, 400 MHz, H−H COSY,
HSQC, HMBC): δ 8.09−8.03 (m, 3.4H, CHarom), 7.61−7.52 (m,
1.7H, CHarom), 7.49−7.25 (m, 28.9H, CHarom), 5.76 (dd, 0.7H, J = 9.5,
10.3 Hz, H-3′α), 5.70 (d, 0.7H, J = 3.9 Hz, H-1′α), 5.47 (s, 0.7H,
CHPhα), 5.41 (s, 1H, CHPhβ), 5.36 (t, 1H, J = 9.8 Hz, H-3′β), 5.10 (d,
0.7H, J = 10.6 Hz, CHH Bnα), 4.93 (d, 1H, J = 10.9 Hz, CHH Bnβ),
4.87 (d, 1H, J = 10.9 Hz, CHH Bnβ), 4.83 (d, 0.7H, J = 10.6 Hz, CHH
Bnα), 4.79 (d, 1H, J = 13.6 Hz, CHH Bnβ), 4.76 (d, 0.7H, J = 13.6 Hz,
CHH Bnα), 4.66−4.62 (m, 2H, CHH Bnβ, H-1′β), 4.61−4.58 (m,
2.4H, CHH Bnα, H-1α, H-1β), 4.31 (dd, 0.7H, J = 10.0, 4.6 Hz, H-6′α),
4.28 (d, 0.7H, J = 9.7 Hz, H-5α), 4.23 (d, 1H, J = 9.9 Hz, H-5β), 4.19−
4.06 (m, 3.4H, H-3α, H-4α, H-4β, H-6′β), 3.91 (t, 1H, J = 9.2 Hz, H-3),
3.85 (s, 2.1H, CH3 CO2Meα), 3.83 (s, 3H, CH3 CO2Meβ), 3.79−3.59
(m, 3.8H, H-2α, H-4′α, H-4′β, H-5′α, H-6′α), 3.59−3.44 (m, 4H, H-2β,
H-2′β, H-5′β, H-6′β), 3.43 (s, 3H, CH3 OMeβ), 3.42 (s, 2.1H, CH3
OMeα), 3.31 (dd, 1H, J = 10.4, 3.9 Hz, H-2′α). 13C-APT NMR
(CDCl3, 101 MHz, HSQC, HMBC): δ 170.2, 169.9 (CO CO2Me),
165.5, 165.3 (CO Bz), 139.1, 138.4, 138.0, 137.7, 137.0, 136.8 (Cq
Bn, CHPh), 133.4, 133.4, 130.0, 130.0 (CHarom), 129.5, 129.5 (Cq Bz),
129.1, 129.1, 128.7, 128.6, 128.5, 128.5, 128.5, 128.3, 128.3, 128.2,
128.1, 127.8, 127.7, 127.6, 127.5, 126.2, 126.2 (CHarom), 102.3 (C-1′β),
101.7 (CHPhα), 101.5 (CHPhβ), 99.0 (C-1′α), 98.8 (C-1β), 98.5 (C-
1α), 81.1 (C-3α), 79.9 (C-2α), 79.5, 79.5 (C-3β, C-4β), 79.2 (C-4′α),
78.9, 78.7 (C-2β, C-4′β), 75.7, 75.4 (CH2 Bn), 75.2 (C-4α), 73.9, 73.6
(CH2 Bn), 71.9 (C-3′β), 69.8, 69.8 (C-5α, C-5β), 69.6 (C-3′α), 68.5,
68.4 (C-6′α, C-6′β), 66.5 (C-5′β), 65.6 (C-2′β), 63.2 (C-5′α), 61.7 (C-
2′α), 56.0, 56.0 (CH3 OMe), 53.1, 53.0 (CH3 CO2Me). HRMS: [M +
NH4]
+ calcd for C42H47N4O12 799.31850, found 799.31869.
2,2-Difluoroethyl 2-Azido-3-O-benzoyl-4,6-O-benzylidene-2-
deoxy-α/β-D-glucopyranoside (4G). Donor 4 and 2,2-difluoroethanol
were condensed using the general procedure for Tf2O/Ph2SO-
mediated glycosylations and purified by flash column chromatography
(1:1:0 to 0:1:0 to 0:19:1 pentane/toluene/EtOAc) to yield
glycosylation product 4G (38.6 mg, 84 μmol, 84%, α/β = 2.7:1) as
a white solid. Rf 0.49 (19:1 toluene/EtOAc). IR (thin film): 709, 997,
1026, 1069, 1094, 1265, 1726, 2108, 2870. Data for the α-anomer: 1H
NMR (CDCl3, 400 MHz, H−H COSY, HSQC): δ 8.11−8.05 (m, 2H,
CHarom), 7.63−7.53 (m, 1H, CHarom), 7.50−7.36 (m, 4H, CHarom),
7.34−7.27 (m, 3H, CHarom), 6.02 (tt, 1H, J = 55.1, 4.2 Hz, CHF2),
5.91−5.81 (m, 1H, H-3), 5.53 (s, 1H, CHPh), 5.11 (d, 1H, J = 3.6 Hz,
H-1), 4.33 (dd, 1H, J = 10.4, 4.9 Hz, H-6), 4.07 (ddd, 1H, J = 14.8, 6.4,
3.7 Hz, H-5), 3.99−3.77 (m, 4H, H-4, H-6), 3.42 (dd, 1H, J = 10.4, 3.6
Hz, H-2). 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 165.5 (C
O Bz), 136.8 (Cq), 133.5, 130.1 (CHarom), 129.5 (Cq Bz), 128.5, 128.3,
126.2 (CHarom), 113.7 (t, J = 241.7 Hz, CHF2), 101.8 (CHPh), 99.8
(C-1), 79.4 (C-4), 69.3 (C-3), 68.7 (C-6), 67.6 (t, J = 29.0 Hz, CH2
CHF2), 63.5 (C-5), 61.8 (C-2). Data for the β-anomer:
1H NMR
(CDCl3, 400 MHz): δ 5.97 (tdd, 0.37H, J = 55.2, 4.8, 3.5 Hz, CHF2),
5.51 (s, 0.37H, CHPh), 5.42 (t, 0.37H, J = 9.8 Hz, H-3), 4.63 (d,
0.37H, J = 7.9 Hz, H-1), 4.38 (dd, 0.37H, J = 10.5, 5.0 Hz, H-6), 4.12−
3.99 (m, 0.37H, CHHCHF2), 3.98−3.76 (m, 1.11H, CHHCHF2,
H-4, H-6), 3.69 (dd, 0.37H, J = 10.0, 7.9 Hz, H-2), 3.58 (td, 0.37H, J =
9.8, 5.0 Hz, H-5). 13C-APT NMR (CDCl3, 101 MHz): δ 165.4, 136.7,
133.5, 130.0, 129.4, 129.2, 128.6, 126.2, 113.8 (t, J = 241.5 Hz), 103.1,
101.7, 78.7 (C-4), 71.5 (C-3), 69.1 (t, J = 29.0 Hz, CH2CHF2), 68.4
(C-6), 66.8 (C-5), 64.9 (C-2). HRMS: [M + H]+ calcd for
C22H22F2N3O6 462.14712, found 462.14699.
Methyl 4-O-(2-Azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α/
β-D-glucopyranosyl)-2,3,6-tri-O-benzyl-β-D-galactopyranoside (4H).
Donor 4 and acceptor 28 were condensed using the general procedure
for Tf2O/Ph2SO-mediated glycosylations (for an additional 18 h at
−40 °C) and purified by flash column chromatography (19:1 to 4:1
pentane/EtOAc) to yield glycosylation product 4H (43 mg, 52 μmol,
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52%, α/β = 4:1) as a white solid. Rf 0.36 (4:1 pentane/EtOAc). IR
(thin film): 698, 737, 997, 1072, 1094, 1265, 1452, 1730, 2106, 2862,
2930. Data for the α-anomer: 1H NMR (CDCl3, 400 MHz, H−H
COSY, HSQC, HMBC): δ 8.12−8.05 (m, 2H, CHarom), 7.57 (t, 1H, J
= 7.4 Hz, CHarom), 7.45 (t, 2H, J = 7.7 Hz, CHarom), 7.42−7.20 (m,
20H, CHarom), 5.85 (t, 1H, J = 9.9 Hz, H-3′), 5.44 (s, 1H, CHPh), 5.07
(d, 1H, J = 3.9 Hz, H-1′), 4.93 (d, 1H, J = 11.0 Hz, CHH Bn), 4.84 (d,
1H, J = 10.9 Hz, CHH Bn), 4.79 (d, 1H, J = 12.4 Hz, CHH Bn), 4.74
(d, 1H, J = 12.4 Hz, CHH Bn), 4.55 (s, 2H, CH2 Bn), 4.46 (td, 1H, J =
9.9, 4.9 Hz, H-5′), 4.26 (d, 1H, J = 7.6 Hz, H-1), 4.17 (d, 1H, J = 3.1
Hz, H-4), 3.93 (t, 1H, J = 9.1 Hz, H-6), 3.85 (dd, 1H, J = 10.2, 5.0 Hz,
H-6′), 3.81−3.70 (m, 2H, H-2, H-4′), 3.64 (dd, 2H, J = 9.1, 5.4 Hz, H-
6), 3.57−3.50 (m, 5H, CH3 OMe, H-5, H-6′), 3.47 (dd, 1H, J = 10.4,
3.9 Hz, H-2′), 3.42 (dd, 1H, J = 10.0, 3.0 Hz, H-3). 13C-APT NMR
(CDCl3, 101 MHz, HSQC, HMBC): δ 165.3 (CO Bz), 138.7,
138.3, 137.6, 137.2 (Cq), 133.3, 130.0 (CHarom), 129.8 (Cq), 128.9,
128.7, 128.6, 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.2, 128.2,
128.1, 127.9, 127.7, 127.6, 127.6, 126.3, 126.2 (CHarom), 105.2 (C-1),
101.4 (CHPh), 99.4 (C-1′), 80.0 (C-4′), 79.8 (C-3), 79.0 (C-2), 75.2
(CH2 Bn), 74.4 (C-4), 73.6, 73.2 (CH2 Bn), 72.6 (C-5), 70.2 (C-3′),
68.8 (C-6′), 67.1 (C-6), 62.8, 62.7 (C-2′, C-5′), 57.0 (OMe).
Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 400 MHz): δ
5.47 (s, 0.25H, CHPh), 5.34 (t, 0.25H, J = 9.8 Hz, H-3′), 4.30 (d,
0.25H, J = 7.7 Hz, H-1′), 4.09 (d, 0.25H, J = 2.7 Hz, H-4). 13C-APT
NMR (CDCl3, 101 MHz): δ 105.1 (C-1), 102.7 (C-1′), 101.5
(CHPh), 81.2, 79.6, 78.9, 75.3, 74.6, 73.9, 73.6, 73.3, 71.7, 69.4, 68.5,
66.2, 65.0, 57.3. HRMS: [M + NH4]




anoside (4I). Donor 4 and acceptor 29 were condensed using the
general procedure for Tf2O/Ph2SO-mediated glycosylations (for an
additional 18 h at −40 °C) and purified by flash column
chromatography (19:1 to 3/1 pentane/EtOAc) to yield glycosylation
product 4I (55 mg, 73 μmol, 73%, α/β = 5:1) as a white solid. Rf 0.36
(4:1 pentane/EtOAc). IR (thin film): 671, 750, 1037, 1092, 1265,
1373, 1730, 2108, 2913. 1H NMR (CDCl3, 400 MHz, H−H COSY,
HSQC, HMBC): δ 8.15−8.04 (m, 2H, CHarom), 7.59−7.53 (m, 1H,
CHarom), 7.53−7.25 (m, 17H, CHarom), 5.92 (dd, 1H, J = 10.4, 9.5 Hz,
H-3′), 5.67 (s, 1H, CHPh), 5.54 (s, 1H, CHPh′), 5.51 (d, 1H, J = 3.8
Hz, H-1′), 4.94 (d, 1H, J = 12.2 Hz, CHH Bn), 4.73 (d, 1H, J = 1.5
Hz, H-1), 4.69 (d, 1H, J = 12.2 Hz, CHH Bn), 4.39 (t, 1H, J = 9.7 Hz,
H-4), 4.32 (dd, 1H, J = 10.4, 4.9 Hz, H-6′), 4.27 (dd, 1H, J = 10.3, 4.7
Hz, H-6), 4.14 (dd, 1H, J = 3.1, 1.6 Hz, H-2), 4.06−3.99 (m, 2H, H-3,
H-5′), 3.95 (t, 1H, J = 10.3 Hz, H-6), 3.86−3.77 (m, 3H, H-4′, H-5,
H-6′), 3.38−3.33 (m, 4H, CH3 OMe, H-2′). 13C-APT NMR (CDCl3,
101 MHz, HSQC): δ 165.5 (CO Bz), 138.8, 137.7, 136.8 (Cq),
133.4, 130.1 (CHarom), 129.6 (Cq), 129.2, 128.9, 128.5, 128.4, 128.3,
128.3, 128.3, 128.3, 127.6, 127.6, 127.4, 126.2, 126.2, 126.2, 126.1
(CHarom), 101.7, 101.6 (CHPh), 100.9 (C-1), 100.1 (C-1′), 79.7 (C-
4′), 79.5 (C-4), 75.9, 75.9 (C-2, C-3), 73.6 (CH2 Bn), 69.2 (C-3′),
68.9 (C-6), 68.8 (C-6′), 64.1 (C-5), 63.3 (C-5′), 61.9 (C-2′), 54.9
(OMe). Diagnostic peaks for the β-anomer: 1H NMR (CDCl3, 400
MHz): δ 5.60 (s, 0.2H, CHPh), 5.50 (s, 0.2H, CHPh), 5.40 (t, 0.2H, J
= 9.8 Hz, H-3′), 4.87 (d, 0.2H, J = 1.4 Hz, H-1), 4.80 (d, 0.2H, J =
12.3 Hz, CHH Bn), 3.57 (td, 0.2H, J = 9.9, 4.3 Hz), 3.40 (s, 0.6H, CH3
OMe). 13C-APT NMR (CDCl3, 101 MHz): δ 101.8 (C-1′), 100.0
(CHPh), 99.4 (C-1), 78.7, 78.5, 76.4, 74.4, 72.4, 71.5, 68.9, 68.5, 66.9,
65.1, 64.2, 55.2. HRMS: [M + NH4]
+ calcd for C41H45N4O11
769.30793, found 769.30780.
2,2,2-Trifluoroethyl 2-Azido-3-O-benzoyl-4,6-O-benzylidene-2-
deoxy-α-D-glucopyranoside (4J). Donor 4 and 2,2,2-trifluoroethanol
were condensed using the general procedure for Tf2O/Ph2SO-
mediated glycosylations (for an additional 30 min at −40 °C) and
purified by flash column chromatography (19:1 to 17:3 pentane/
EtOAc) to yield glycosylation product 4J (41 mg, 86 μmol, 86%, α/β
> 20:1) as a white solid. Rf 0.15 (toluene). [α]D
20 = +78.9° (c = 1.03,
CHCl3). IR (thin film): 702, 989, 1085, 1177, 1275, 1717, 2112, 2864.
1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC): δ 8.13−8.03 (m,
2H, CHarom), 7.60−7.53 (m, 1H, CHarom), 7.48−7.38 (m, 4H,
CHarom), 7.33−7.28 (m, 3H, CHarom), 5.87 (t, 1H, J = 10.0 Hz, H-
3), 5.53 (s, 1H, CHPh), 5.14 (d, 1H, J = 3.6 Hz, H-1), 4.33 (dd, 1H, J
= 10.4, 4.9 Hz, H-6), 4.14−3.97 (m, 4H, CH2CF3, H-5), 3.84 (t, 1H, J
= 9.5 Hz, H-4), 3.80 (t, 1H, J = 10.3 Hz, H-6), 3.44 (dd, 1H, J = 10.4,
3.6 Hz, H-2). 13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 165.5
(CO), 136.7 (Cq), 133.5, 130.0 (CHarom), 129.5 (Cq Bz), 129.2,
128.5, 127.6, 126.2 (CHarom), 123.42 (q, J = 278.6 Hz), 101.8 (CHPh),
99.9 (C-1), 79.3 (C-4), 69.1 (C-3), 68.6 (C-6), 65.41 (q, J = 35.6 Hz),
63.7 (C-5), 61.6 (C-2). HRMS: [M + NH4]
+ calcd for C22H24F3N4O6
497.16425, found 497.16425.
Ethyl 3-O-Benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyr-
idone)-β-D-glucopyranoside (5A). Donor 5 and ethanol were
condensed using the general procedure for Tf2O/Ph2SO-mediated
glycosylations (for an additional 1 h at −40 °C) and purified by flash
column chromatography (19:1 to 8:2 pentane/EtOAc) to yield
glycosylation product 5A (32 mg, 59 μmol, 59%, α/β < 1:20) as a
yellow solid alongside donor 5 (14 mg). Rf 0.60 (7:3 pentane/EtOAc).
[α]D
23 = +156.9° (c = 0.64, CHCl3). IR (thin film): 698, 998, 1093,
1213, 1303, 1330, 1516, 1679, 2930. 1H NMR (CDCl3, 400 MHz, H−
H COSY, HSQC): δ 8.58 (s, 2H, CH pyridone), 7.56 (dd, 2H, J = 7.4,
2.2 Hz, CHarom), 7.45−7.38 (m, 3H, CHarom), 7.06−6.97 (m, 5H,
CHarom), 5.66 (s, 1H, CHPh), 5.32 (d, 1H, J = 8.3 Hz, H-1), 4.70 (d,
1H, J = 11.7 Hz, CHH Bn), 4.57 (dd, 1H, J = 10.2, 8.7 Hz, H-3), 4.53
(d, 1H, J = 11.6 Hz, CH H Bn), 4.43 (dd, 1H, J = 10.3, 4.6 Hz, H-6),
3.99−3.81 (m, 4H, CHH Et, H-4, H-5, H-6), 3.72 (dd, 1H, J = 10.3,
8.3 Hz, H-2), 3.60 (dq, 1H, J = 9.9, 7.1 Hz, CHH Et), 1.08 (t, 3H, J =
7.1 Hz, CH3 Et).
13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 160.6
(CO pyridone), 141.7 (Cq NO2 pyridone), 141.4 (CH pyridone),
137.1, 136.6 (Cq), 129.4, 128.9, 128.7, 128.5, 128.5, 126.3 (CHarom),
101.9 (CHPh), 99.3 (C-1), 82.8 (C-4), 75.4 (C-3), 74.9 (CH2 Bn),
73.8 (C-2), 68.7 (C-6), 66.5 (CH2 Et), 65.7 (C-5), 15.1 (CH3 Et).
HRMS: [M + H]+ calcd for C27H28N3O10 554.17692, found
554.17642.
Cyclohexyl 3-O-Benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-
4-pyridone)-β-D-glucopyranoside (5B). Donor 5 and cyclohexanol
were condensed using the general procedure for Tf2O/Ph2SO-
mediated glycosylations (for an additional 1 h at −40 °C) and
purified by flash column chromatography (19:1 to 8:2 pentane/
EtOAc) to yield 51 mg of glycosylation product 5B as an inseperable
mixture with donor 5 (13 mg of 5, 38 mg of 5B, 63 μmol, 63%, α/β <
1:20) as a yellow solid. Rf 0.75 (7:3 pentane/EtOAc). Rf 0.55 (7:3
pentane/EtOAc). IR. (thin film): 697, 718, 749, 789, 910, 997, 1092,
1212, 1302, 1330, 1516, 1623, 1674, 2931. 1H NMR (CDCl3, 400
MHz, H−H COSY, HSQC): δ 8.60 (s, 2H, CH pyridone), 7.56 (d,
2H, J = 4.7 Hz, CHarom), 7.48−7.33 (m, 3H, CHarom), 7.10−6.96 (m,
5H, CHarom), 5.65 (s, 1H, CHPh), 5.41 (d, 1H, J = 8.2 Hz, H-1), 4.71
(d, 1H, J = 11.7 Hz, CHH Bn), 4.66−4.50 (m, 2H, CHH Bn, H-3),
4.44 (dd, 1H, J = 10.6, 5.2 Hz, H-6), 3.98−3.80 (m, 3H, H-4, H-5, H-
6), 3.79−3.61 (m, 2H, CH Cy, H-2), 1.91−1.77 (m, 1H, CH2 Cy),
1.71−1.54 (m, 2H, CH2 Cy), 1.54−1.45 (m, 1H, CH2 Cy), 1.43−0.96
(m, 6H, CH2 Cy).
13C-APT NMR (CDCl3, 101 MHz, HSQC): δ
160.5 (CO pyridone), 141.6 (Cq NO2 pyridone), 141.4 (CH
pyridone), 137.1, 136.7 (Cq), 128.8, 128.6, 128.4, 126.3 (CHarom),
101.9 (CHPh), 98.1 (C-1), 82.7 (C-4), 78.8 (CH Cy), 75.6 (C-3),
74.8 (CH2 Bn), 74.0 (C-2), 68.8 (C-6), 65.7 (C-5), 33.3, 31.7, 25.3,
23.9, 23.6 (CH2 Cy). HRMS: [M + H]




pyranoside (3C). Donor 5 and acceptor 25 were condensed using the
general procedure for Tf2O/Ph2SO-mediated glycosylations (for an
additional 18 h at −40 °C) and purified by flash column
chromatography (9:1 to 7:3 pentane/EtOAc) to yield glycosylation
product 5C (55 mg, 54 μmol, 54%, α/β < 1:20) as a yellow solid. Rf
0.45 (7:3 pentane/EtOAc). [α]D
20 = +90.5° (c = 0.92, CHCl3). IR (thin
film): 698, 1001, 1069, 1094, 1213, 1331, 1454, 1522, 1678, 2868. 1H
NMR (CDCl3, 400 MHz, H−H COSY, HSQC, HMBC): δ 8.19 (s,
2H, CH pyridone), 7.54 (dd, 2H, J = 7.6, 2.1 Hz, CHarom), 7.45−7.38
(m, 3H, CHarom), 7.34−7.22 (m, 13H, CHarom), 7.20−7.12 (m, 5H,
CHarom), 7.04 (dd, 2H, J = 6.6, 2.9 Hz, CHarom), 5.66 (s, 1H, CHPh),
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4.92 (d, 1H, J = 11.0 Hz, CHH Bn), 4.85 (d, 1H, J = 8.3 Hz, H-1′),
4.83−4.66 (m, 2H, 2 × CHH Bn), 4.72 (d, 1H, J = 10.9 Hz, CHH
Bn), 4.69 (d, 1H, J = 12.0 Hz, CHH Bn), 4.60 (d, 1H, J = 12.2 Hz,
CHH Bn), 4.60 (d, 1H, J = 12.0 Hz, CHH Bn), 4.46 (d, 1H, J = 3.4
Hz, H-1), 4.39 (dd, 1H, J = 10.6, 5.0 Hz, H-6′), 4.34 (d, 1H, J = 11.3
Hz, CHH Bn), 4.10 (t, 1H, J = 7.9 Hz, H-3′), 4.01 (dd, 1H, J = 10.8,
1.8 Hz, H-6), 3.91 (t, 1H, J = 9.2 Hz, H-3), 3.89−3.82 (m, 2H, H-4′,
H-6), 3.77−3.69 (m, 2H, H-2′, H-5), 3.65 (td, 1H, J = 9.7, 5.0 Hz, H-
5′), 3.52 (dd, 1H, J = 10.8, 7.1 Hz, H-6), 3.39 (dd, 1H, J = 9.6, 3.5 Hz,
H-2), 3.21 (s, 3H, CH3 OMe), 3.13 (dd, 1H, J = 9.9, 8.9 Hz, H-4).
13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 159.4 (CO
pyridone), 141.7 (Cq NO2 pyridone), 140.2 (CH pyridone), 138.6,
138.0, 138.0, 136.7, 135.8 (Cq), 129.5, 129.1, 129.0, 128.6, 128.5,
128.5, 128.5, 128.2, 128.1, 128.0, 128.0, 127.9, 127.7, 127.6, 126.1
(CHarom), 101.8 (CHPh), 100.1 (C-1′), 97.9 (C-1), 82.3 (C-4′), 81.6
(C-3), 79.8 (C-2), 78.2 (C-4), 75.7, 74.8, 74.3, (CH2 Bn), 74.0 (C-3′),
73.3 (CH2 Bn), 72.7 (C-2′), 70.4 (C-6), 69.3 (C-5), 68.4 (C-6′), 66.1
(C-5′), 55.1 (OMe). 13C-HMBC-GATED NMR (CDCl3, 101 MHz):
δ 100.1 (J = 163 Hz, C-1′). HRMS: [M + H]+ calcd for C53H54N3O15
972.35494, found 972.35546.
2-Fluoroethyl 3-O-Benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dini-
tro-4-pyridone)-β-D-glucopyranoside (5D). Donor 5 and 2-fluoroe-
thanol were condensed using the general procedure for Tf2O/Ph2SO-
mediated glycosylations (for an additional 1 h at −40 °C) and purified
by flash column chromatography (19:1 to 8:2 pentane/EtOAc) to
yield glycosylation product 5D (24 mg, 43 μmol, 43%, α/β < 1:20) as
a yellow solid alongside donor 5 (15.6 mg). Rf 0.42 (3/2 pentane/
EtOAc). [α]D
23 = +142.9° (c = 0.48, CHCl3). IR (thin film): 698, 752,
1070, 1096, 1213, 1304, 1331, 1518, 1680, 2870, 3064. 1H NMR
(CDCl3, 400 MHz, H−H COSY, HSQC): δ 8.58 (s, 2H, CH
pyridone), 7.63−7.49 (m, 2H, CHarom), 7.47−7.36 (m, 3H, CHarom),
7.09−6.96 (m, 5H, CHarom), 5.66 (s, 1H, CHPh), 5.46 (d, 1H, J = 8.3
Hz, H-1), 4.71 (d, 1H, J = 11.7 Hz, CHH Bn), 4.57 (dd, 1H, J = 10.3,
8.7 Hz, H-3), 4.53 (d, 1H, J = 11.7 Hz, CHH Bn), 4.48−4.42 (m, 2H,
CHHF, H-6), 4.33 (t, 1H, J = 4.1 Hz, CHHF), 4.09−3.81 (m, 5H,
CH2CH2F, H-4, H-5, H-6), 3.77 (dd, 1H, J = 10.3, 8.4 Hz, H-2).
13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 160.6 (CO
pyridone), 141.5, 141.5 (Cq NO2, CH pyridone), 137.0, 136.6 (Cq),
129.4, 129.0, 128.7, 128.6, 128.5, 126.3 (CHarom), 101.9 (CHPh), 99.8
(C-1), 82.7 (C-4), 82.5 (d, J = 169.4 Hz, CH2F), 75.3 (C-3), 74.9
(CH2 Bn), 73.6 (C-2), 69.5 (d, J = 19.5 Hz, CH2CH2F), 68.6 (C-6),




pyranoside (5E). Donor 5 and acceptor 26 were condensed using the
general procedure for Tf2O/Ph2SO-mediated glycosylations (for an
additional 18 h at −40 °C) and purified by flash column
chromatography (9:1 to 7:3 pentane/EtOAc) to yield glycosylation
product 5E (54 mg, 56 μmol, 56%, α/β < 1:20) as a yellow solid. Rf
0.37 (7:3 pentane/EtOAc). [α]D
23 = +83.3° (c = 0.84, CHCl3). IR (thin
film): 696, 734, 997, 1028, 1039, 1092, 1209, 1302, 1327, 1454, 1522,
1682, 2862, 2900, 3030, 3065. 1H NMR (CDCl3, 500 MHz, H−H
COSY, HSQC, HMBC, NOESY): δ 7.74 (s, 2H, CH pyridone), 7.57−
7.53 (m, 2H, CHarom), 7.49−7.38 (m, 8H, CHarom), 7.36−7.25 (m,
13H, CHarom), 7.04−7.00 (m, 2H, CHarom), 5.57 (s, 1H, CHPh), 4.90
(d, 1H, J = 11.7 Hz, CHH Bn), 4.77 (d, 1H, J = 12.1 Hz, CHH Bn),
4.74 (d, 1H, J = 12.3 Hz, CHH Bn), 4.69 (d, 1H, J = 11.7 Hz, CHH
Bn), 4.66 (d, 1H, J = 12.0 Hz, CHH Bn), 4.63 (d, 1H, J = 12.1 Hz,
CHH Bn), 4.56 (d, 1H, J = 12.3 Hz, CHH Bn), 4.54 (d, 1H, J = 3.6
Hz, H-1), 4.35 (d, 1H, J = 8.2 Hz, H-1′), 4.27−4.20 (m, 2H, CHH Bn,
H-6′), 3.92 (t, 1H, J = 9.5 Hz, H-4), 3.70 (t, 1H, J = 9.3 Hz, H-3), 3.67
(t, 1H, J = 9.0 Hz, H-4′), 3.58 (t, 1H, J = 10.4 Hz, H-6′), 3.53−3.45
(m, 2H, H-2, H-3′), 3.43 (dd, 1H, J = 11.4, 1.5 Hz, H-6), 3.40−3.34
(m, 1H, H-5), 3.31 (s, 2H, CH3 OMe), 3.18 (dd, 1H, J = 10.5, 8.3 Hz,
H-2′), 3.04 (dd, 1H, J = 11.3, 2.6 Hz, H-6), 2.92 (td, 1H, J = 9.8, 5.1
Hz, H-5′). 13C-APT NMR (CDCl 3, 126 MHz, HSQC, HMBC): δ
159.3 (CO pyridone), 141.8 (Cq NO2 pyridone), 139.6 (CH
pyridone), 139.4, 138.1, 137.8, 136.8, 135.7 (Cq), 129.6, 129.3, 129.2,
129.0, 128.9, 128.6, 128.6, 128.5, 128.4, 128.1, 128.1, 127.8, 126.1
(CHarom), 101.8 (CHPh), 98.1 (C-1), 97.6 (C-1′), 82.4 (C-4′), 79.7
(C-2), 79.2 (C-3), 75.3 (CH2 Bn), 74.4 (C-4), 73.9, 73.6, 73.5 (CH2
Bn), 73.0 (C-3′), 72.5 (C-2′), 69.2 (C-5), 68.4 (C-6′), 68.1 (C-6),




glucopyranosyl uronate) (5F). Donor 5 and acceptor 27 were
condensed using the general procedure for Tf2O/Ph2SO-mediated
glycosylations (for an additional 18 h at −40 °C) and purified by flash
column chromatography (9:1 to 7:3 pentane/EtOAc) to yield
glycosylation product 5F (27 mg, 30 μmol, 30%, α/β = 1:3.6) as a
yellow solid. Rf 0.51 (7:3 pentane/EtOAc). IR (thin film): 648, 698,
733, 789, 910, 995, 1090, 1171, 1209, 1302, 1331, 1454, 1520, 1678,
1744, 2932. Data for the β-anomer: 1H NMR (CDCl3, 500 MHz, H−
H COSY, HSQC, HMBC): δ 8.06 (s, 2H, CH pyridone), 7.50 (dd,
2H, J = 7.3, 2.0 Hz, CHarom), 7.45−7.35 (m, 6H, CHarom), 7.33−7.18
(m, 9H, CHarom), 7.03 (dd, 2H, J = 6.9, 2.2 Hz, CHarom), 6.96 (dd, 1H,
J = 14.5, 6.9 Hz, CHarom), 5.55 (s, 1H, CHPh), 5.17 (d, 1H, J = 8.2 Hz,
H-1′), 4.92 (d, 1H, J = 11.3 Hz, CHH Bn), 4.82−4.72 (m, 3H, CHH
Bn, 2 × CHH Bn), 4.61−4.55 (m, 2H, 2 × CHH Bn), 4.51 (d, 1H, J =
3.3 Hz, H-1), 4.14 (dd, 1H, J = 10.6, 4.8 Hz, H-6′), 3.97−3.88 (m, 2H,
H-3′, H-4), 3.83 (d, 1H, J = 9.7 Hz, H-5), 3.82−3.73 (m, 2H, H-3, H-
4′), 3.54−3.43 (m, 6H, CH3 CO2Me, H-2, H-2′, H-5′), 3.42−3.36 (m,
4H, CH3 OMe, H-6′). 13C-APT NMR (CDCl3, 126 MHz, HSQC,
HMBC): δ 170.0 (CO CO2Me), 159.5 (CO pyridone), 141.5
(Cq NO2 pyridone), 140.4 (CH pyridone), 139.1, 137.8, 136.7, 135.7
(Cq), 129.5, 129.2, 129.2, 129.1, 129.0, 128.9, 128.7, 128.7, 128.6,
128.5, 128.4, 128.2, 128.2, 127.7, 127.7, 126.1, 126.0, 125.7 (CHarom),
101.7 (CHPh), 98.8 (C-1′), 98.3 (C-1), 82.3 (C-4′), 79.1 (C-3), 78.8
(C-2), 77.8 (C-4), 75.5, 74.2 (CH2 Bn), 74.0 (C-3′), 73.7 (CH2 Bn),
72.9 (C-2′), 68.8 (C-5), 68.2 (C-6′), 65.9 (C-5′), 56.1 (OMe), 52.9
(CO2Me).
13C-HMBC-GATED NMR (CDCl3, 101 MHz): δ 98.8 (J
= 167 Hz, C-1′). Diagnostic peaks for the α-anomer: 1H NMR
(CDCl3, 500 MHz, H−H COSY, HSQC): δ 5.74 (d, 0.28H, J = 3.9
Hz, H-1′), 5.61 (s, 0.28H, CHPh), 5.03 (d, 0.28H, J = 12.7 Hz, CHH
Bn), 4.70 (d, 0.28H, J = 12.3 Hz), 4.62 (d, 0.28H, J = 12.2 Hz, CHH
Bn), 4.46 (d, 0.28H, J = 12.3 Hz, CHH Bn), 4.37 (dd, 0.28H, J = 10.5,
4.9 Hz, H-6′), 4.29 (d, 0.28H, J = 9.9 Hz, H-5), 4.08 (t, 0.28H, J = 9.4
Hz), 3.69 (dd, 0.28H, J = 10.6, 3.9 Hz, H-2′). 13C-APT NMR (CDCl3,
126 MHz, HSQC): δ 169.7, 159.2, 141.2, 101.8 (CHPh), 96.8 (C-1′),
82.6, 80.7, 79.8, 74.5, 74.4, 73.1, 72.2, 69.6, 69.5, 68.1, 63.0, 56.1, 53.3.
13C-HMBC-GATED NMR (CDCl3, 101 MHz): δ 96.8 (J = 181 Hz,
C-1′). HRMS: [M + H]+ calcd for C47H48N3O16 910.30291, found
910.30315.
2,2-Difluoroethyl 3-O-Benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-
dinitro-4-pyridone)-α/β-D-glucopyranoside (5G). Donor 5 and 2,2-
difluoroethanol were condensed using the general procedure for
Tf2O/Ph2SO-mediated glycosylations (for an additional 1 h at −40
°C) and purified by flash column chromatography (19:1 to 8:2
pentane/EtOAc) to yield glycosylation product 5G (17.3 mg, 29 μmol
of α-anomer; 17.8 mg, 30 μmol of β-anomer; α/β = 1:1; 59%) as a
yellow solid alongside donor 5 (11 mg). Rf 0.12 and 0.30 (7:3
pentane/EtOAc). IR (thin film): 698, 997, 1069, 1094, 1211, 1300,
1339, 1520, 1684, 2922. Data for the α-anomer: 1H NMR (acetone-d6,
400 MHz, H−H COSY, HSQC): δ 8.91 (s, 2H, CH pyridone), 7.61−
7.53 (m, 2H, CHarom), 7.48−7.37 (m, 3H, CHarom), 7.25−7.10 (m, 5H,
CHarom), 6.16 (tt, 1H, J = 55.0, 3.7 Hz, CHF2), 5.83 (s, 1H, CHPh),
5.56 (d, 1H, J = 3.7 Hz, H-1), 4.91 (d, 1H, J = 11.9 Hz, CHH Bn),
4.79 (dd, 1H, J = 10.7, 3.7 Hz, H-2), 4.71−4.62 (m, 2H, CHH Bn, H-
3), 4.37 (dd, 1H, J = 10.1, 4.9 Hz, H-6), 4.18−4.06 (m, 2H, CHH
CHF2, H-5), 4.03 (dd, 1H, J = 9.6, 8.6 Hz, H-4), 3.96−3.83 (m, 2H,
CHHCHF2, H-6). 13C-APT NMR (acetone-d6, 101 MHz, HSQC):
δ 160.0 (CO pyridone), 142.9 (Cq NO2 pyridone), 142.6 (CH
pyridone), 138.6, 138.5 (Cq), 129.8, 129.2, 129.0, 129.0, 128.9, 127.0
(CHarom), 115.0 (t, J = 239.2 Hz, CHF2), 102.1 (CHPh), 98.8 (C-1),
83.5 (C-4), 75.0 (CH2 Bn), 74.7 (C-3), 69.9 (C-2), 68.9 (C-6), 67.93
(t, J = 27.3 Hz, CH2CHF2), 63.9 (C-5). Data for the β-anomer: 1H
NMR (CDCl3, 400 MHz, H−H COSY, HSQC): δ 8.67 (s, 2H, CH
pyridone), 7.60−7.52 (m, 2H, CHarom), 7.46−7.37 (m, 3H, CHarom),
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7.03−6.93 (m, 5H, CHarom), 5.75 (tt, 1H, J = 54.9, 3.9 Hz, CHF2),
5.65 (s, 1H, CHPh), 5.59 (d, 1H, J = 8.3 Hz, H-1), 4.76−4.64 (m, 2H,
CHH Bn, H-3), 4.50 (d, 1H, J = 11.6 Hz, CHH Bn), 4.45 (dd, 1H, J =
10.4, 4.9 Hz, H-6), 4.05 (td, 1H, J = 9.7, 5.0 Hz, H-5), 4.00−3.80 (m,
4H, CH2CHF2, H-4, H-6), 3.77 (dd, 1H, J = 10.3, 8.4 Hz, H-2).
13C-APT NMR (CDCl3, 101 MHz, HSQC): δ 160.9 (CO
pyridone), 141.7 (Cq NO2 pyridone), 141.5 (CH pyridone), 137.0,
136.7 (Cq), 129.4, 128.8, 128.6, 128.5, 128.4, 126.4 (CHarom), 113.4 (t,
J = 241.5 Hz, 102.0 (CHPh), 99.9 (C-1), 82.6 (C-4), 75.5 (C-3), 75.1
(CH2 Bn), 73.7 (C-2), 68.9 (t, J = 27.8 Hz, CH2CHF2), 68.6 (C-6),




pyranoside (5H). Donor 5 and acceptor 28 were condensed using the
general procedure for Tf2O/Ph2SO-mediated glycosylations (for an
additional 18 h at −40 °C) and purified by flash column
chromatography (9:1 to 7:3 pentane/EtOAc) to yield glycosylation
product 5H (51 mg, 52 μmol, 52%, α/β < 1:20) as a yellow solid. Rf
0.49 (7:3 pentane/EtOAc). [α]D
20 = +35.5° (c = 0.85, CHCl3). IR (thin
film): 698, 750, 999, 1072, 1094, 1213, 1454, 1522, 1682, 2868. 1H
NMR (CDCl3, 400 MHz, H−H COSY, HSQC, HMBC): δ 8.20 (s,
2H, CH pyridone), 7.55−7.49 (m, 2H, CHarom), 7.47−7.40 (m, 3H,
CHarom), 7.40−7.15 (m, 18H, CHarom), 7.07−7.00 (m, 2H, CHarom),
5.63 (s, 1H, CHPh), 5.03 (d, 1H, J = 8.3 Hz, H-1′), 4.80 (d, 1H, J =
12.2 Hz, CHH Bn), 4.64 (d, 1H, J = 10.4 Hz, CHH Bn), 4.61 (d, 1H, J
= 12.3 Hz, CHH Bn), 4.57 (d, 1H, J = 12.2 Hz, CHH Bn), 4.50 (s, 2H,
CH2 Bn), 4.47 (d, 1H, J = 12.3 Hz, CHH Bn), 4.29 (d, 1H, J = 10.4
Hz, CHH Bn), 4.20 (dd, 1H, J = 10.5, 5.0 Hz, H-6′), 4.13 (d, 1H, J =
7.6 Hz, H-1), 3.91 (d, 1H, J = 2.6 Hz, H-4), 3.88−3.78 (m, 2H, H-3′,
H-4′), 3.74 (t, 1H, J = 10.3 Hz, H-6′), 3.70 (dd, 1H, J = 9.9, 8.4 Hz, H-
2′), 3.66−3.52 (m, 2H, H-6, H-6), 3.46 (s, 4H, CH3 OMe, H-5),
3.41−3.33 (m, 2H, H-3, H-5′), 2.93 (dd, 1H, J = 9.6, 7.6 Hz, H-2).
13C-APT NMR (CDCl3, 101 MHz, HSQC, HMBC): δ 159.4 (Cq
pyridone), 141.6 (Cq NO 2 pyridone), 140.5 (CH pyridone), 138.2,
138.0, 137.6, 136.6, 135.6 (Cq), 129.6, 129.3, 129.1, 129.1, 128.9,
128.7, 128.6, 128.6, 128.4, 128.4, 128.1, 128.0, 127.7, 127.5, 126.1
(CHarom), 104.8 (C-1), 101.8 (CHPh), 99.6 (C-1′), 82.3 (C-4′), 80.2,
80.2 (C-2, C-3), 75.4 (CH2 Bn), 74.6 (C-4), 74.5, 74.4 (CH2 Bn), 74.2
(C-3′), 73.5 (CH2 Bn), 72.5 (C-5), 72.3 (C-2′), 68.6 (C-6), 68.2 (C-
6′), 66.2 (C-5′), 57.3 (OMe). 13C-HMBC-GATED NMR (CDCl3,
101 MHz): δ 104.8 (J = 159 Hz, C-1), 99.6 (J = 165 Hz, C-1′).




dene-α-D-mannopyranoside (5I). Donor 5 and acceptor 29 were
condensed using the general procedure for Tf2O/Ph2SO-mediated
glycosylations (for an additional 18 h at −40 °C) and purified by flash
column chromatography (9:1 to 7:3 pentane/EtOAc) to yield
glycosylation product 5I (47 mg, 53 μmol, 53%, α/β = 1:1.3) as a
yellow solid. Rf 0.34 and 0.49 (7:3 pentane/EtOAc). IR: (thin film):
646, 696, 731, 789, 908, 997, 1090, 1123, 1211, 1302, 1333, 1454,
1518, 1624, 1674, 2910. Data reported for a 0.8:1 mixture of anomers:
1H NMR (CDCl3, 400 MHz, H−H COSY, HSQC, HMBC): δ 8.48 (s,
2H, pyridoneβ), 8.33 (s, 1.6H, pyridoneα), 7.58−7.26 (m, 22.8H,
CHarom), 7.23−7.01 (m, 11.8H, CHarom), 6.99−6.94 (m, 1.6H,
CHarom), 5.67 (s, 1.8H, CHPh′α, CHPh′β), 5.62 (s, 0.8H, CHPhα),
5.53 (s, 1H, CHPhβ), 5.27 (d, 0.8H, J = 3.9 Hz, H-1′α), 5.24 (d, 1H, J
= 8.3 Hz, H-1′β), 4.84 (d, 1H, J = 12.1 Hz, CHH Bnβ), 4.79 (d, 0.8H, J
= 12.2 Hz, CHH Bnα), 4.75 (d, 1H, J = 12.1 Hz, CHH Bnβ), 4.70 (d,
1H, J = 12.2 Hz, CHH Bnβ), 4.67 (d, 0.8H, J = 1.1 Hz, H-1α), 4.64 (d,
1H, J = 12.1 Hz, CHH Bnβ), 4.57 (d, 0.8H, J = 12.2 Hz, CHH Bnα),
4.52 (d, 0.8H, J = 11.1 Hz, CHH Bnα), 4.50 (dd, 1H, J = 10.3, 8.2 Hz,
H-3′β), 4.46−4.41 (m, 1H, H-6′β), 4.33 (d, 0.8H, J = 11.1 Hz, CHH
Bnα), 4.34−4.26 (m, 1.6H, H-6α, H-6′α), 4.22−4.15 (m, 2.8H, H-1β,
H-2β, H-3′α), 4.10−3.96 (m, 4.4H, H-2α, H-2′α, H-2′β, H-5′α, H-6β),
3.95−3.83 (m, 8.2H, H-3α, H-3β, H-4β, H-4′α, H-4′β, H-5′β, H-6α, H-
6′α, H-6′β), 3.81−3.74 (m, 1.6H, H-4α, H-5α), 3.61 (dq, 1H, J = 9.0,
4.5 Hz, H-5β), 3.50 (t, 1H, J = 10.3 Hz, H-6β), 3.38 (s, 2.4H, CH3
OMeα), 3.15 (s, 3H, CH3 OMeβ).
13C-APT NMR (CDCl3, 101 MHz,
HSQC, HMBC): δ 159.9, 159.7 (C = O pyridone), 142.1 (CH
pyridoneα), 141.7 (Cq NO2 pyridone), 140.9 (CH pyridoneβ), 140.8
(Cq NO2 pyridone), 138.2, 137.6, 137.4, 137.4, 136.8, 136.6, 136.5,
136.0 (Cq), 129.6, 129.4, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6,
128.5, 128.4, 128.4, 128.3, 128.3, 127.8, 127.8, 127.6, 126.2, 126.1,
126.1 (CHarom), 101.9, 101.8 (CHPh′α,β), 101.6, 101.6 (CHPhα,β),
100.7 (C-1α), 99.8 (C-1′α), 99.2 (C-1β), 98.8 (C-1′β), 83.1 (C-4′α),
82.4 (C-4′β), 79.6 (C-4α), 79.1 (C-2α), 78.5 (C-4β), 76.1 (C-2β), 75.0
(C-3α), 74.5, 74.5, 74.3 (CH2 Bn), 74.2 (C-3β, C-3′β), 72.9 (C-2′β),
72.7 (CH2 Bn), 72.5 (C-3′α), 69.9 (C-2′α), 68.5, 68.5, 68.4 (C-6α,β, C-
6′α,β), 66.1 (C-5′β), 63.7 (C-5β), 63.3 (C-5α), 63.1 (C-5′α), 55.1, 55.1
(OMe). 13C-HMBC-GATED NMR (CDCl3, 101 MHz): δ 99.8 (J =
176 Hz, C-1′α), 98.8 (J = 164 Hz, C-1′β). HRMS: [M + H]+ calcd for
C46H46N3O15 880.29234, found 880.29252.
2,2,2-Trifluoroethyl 3-O-Benzyl-4,6-O-benzylidene-2-deoxy-2-
(3,5-dinitro-4-pyridone)-α/β-D-glucopyranoside (5J). Donor 5 and
2,2,2-trifluoroethanol were condensed using the general procedure for
Tf2O/Ph2SO-mediated glycosylations (for an additional 1 h at −40
°C) and purified by flash column chromatography (19:1 to 8:2
pentane/EtOAc) to yield glycosylation product 5J (28 mg, 46 μmol of
α-anomer; 7 mg, 12 μmol of β-anomer; α/β = 4:1; 58%) as a yellow
solid alongside glucal 24 (4 mg) and donor 5 (13 mg). Rf 0.15 and
0.67 (7:3 pentane/EtOAc). IR (thin film): 698, 754, 1001, 1071, 1096,
1169, 1215, 1279, 1304, 1331, 1520, 1680, 2855, 2924, 3065. Data for
the α-anomer: 1H NMR (acetone-d6, 400 MHz, H−H COSY,
HSQC): δ 8.92 (s, 2H, CH pyridone), 7.60−7.54 (m, 2H, CHarom),
7.47−7.37 (m, 3H, CHarom), 7.24−7.13 (m, 5H, CHarom), 5.84 (s, 1H,
CHPh), 5.65 (d, 1H, J = 3.7 Hz, H-1), 4.92 (d, 1H, J = 11.8 Hz, CHH
Bn), 4.84 (dd, 1H, J = 10.7, 3.7 Hz, H-2), 4.73 (dd, 1H, J = 10.7, 8.4
Hz, H-3), 4.70 (d, 1H, J = 11.8 Hz, CHH Bn), 4.51−4.38 (m, 1H,
CHHCF3), 4.38 (dd, 1H, J = 10.1, 4.7 Hz, H-6), 4.30−4.17 (m, 1H,
CHHCF3), 4.12 (dd, 1H, J = 9.8, 4.7 Hz, H-5), 4.09−4.02 (m, 1H,
H-4), 3.93 (t, 1H, J = 10.0 Hz, H-6). 13C-APT NMR (acetone-d6, 101
MHz, HSQC): δ 160.0 (CO pyridone), 142.9 (Cq NO2 pyridone),
142.6 (CH pyridone), 138.6, 138.5 (Cq), 129.8, 129.2, 129.0, 129.0,
128.9, 127.0 (CHarom), 124.72 (q, J = 277.4 Hz, CF3), 102.1 (CHPh),
98.8 (C-1), 83.4 (C-4), 75.1 (CH2 Bn), 74.6 (C-3), 69.8 (C-2), 68.8
(C-6), 65.84 (q, J = 35.0 Hz, CH2CF3), 64.1 (C-5). Diagnostic
peaks for the β-anomer: 1H NMR (CDCl3, 400 MHz, H−H COSY,
HSQC): δ 8.61 (s, 2H, CH pyridone), 7.56 (dd, 2H, J = 6.6, 2.9 Hz,
CHarom), 7.41 (dd, 3H, J = 5.0, 1.7 Hz, CHarom), 7.00 (s, 5H, CHarom),
5.66 (s, 1H, CHPh), 5.58 (d, 1H, J = 8.3 Hz, H-1), 4.75−4.62 (m, 2H,
CHH Bn, H-3), 4.52 (d, 1H, J = 11.7 Hz, CHH Bn), 4.46 (dd, 1H, J =
10.5, 4.8 Hz, H-6), 4.17−3.99 (m, 3H, CH2CF3, H-5), 3.91−3.82
(m, 2H, H-4, H-6), 3.78 (dd, 1H, J = 10.0, 8.5 Hz, H-2). HRMS: [M +
H]+ calcd for C27H25F3N3O10 608.14865, found 608.14825.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.joc.7b00470.
NMR spectra of all new compounds, decomposition
study and identification of anomeric triflates by NMR
spectroscopy, 1H NMR spectra of isolated disaccharide
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(35) Chiara, J. L.; García, Á.; Cristob́al-Lumbroso, G. J. Org. Chem.
2005, 70 (10), 4142−4151.
(36) Trans-amination by double Michael addition−elimination with a
nucleophilic amine ensures deprotection. Typical conditions included
0.2 M solution of DNPY-protected compound in pyridine at room
temperature treated with amine (2 equiv) and stirred for 30 min.
Extractive workup gave deprotected amines in excellent yield (>90%).
Efficient nucleophilic amines are ethylenediamine (DNPY product is
water-soluble), propylamine, hexylamine, and hydrazine.
(37) Frihed, T. G.; Bols, M.; Pedersen, C. M. Chem. Rev. 2015, 115
(11), 4963−5013.
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